

**UNIVERSIDADE FEDERAL DE SANTA MARIA
CENTRO DE CIÊNCIAS NATURAIS E EXATAS
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS BIOLÓGICAS: BIOQUÍMICA
TOXICOLÓGICA**

Rodrigo Pereira Martins

**EFEITOS DOS RECURSOS TERAPÊUTICOS SOBRE MARCADORES
BIOQUÍMICOS NA LESÃO MUSCULAR POR ESTIRAMENTO EM RATOS**

**Santa Maria, RS, Brasil
2018**

PPG BTOX\UFSM, RS

MARTINS, Rodrigo Pereira

Rodrigo Pereira Martins

**EFEITOS DOS RECURSOS TERAPÊUTICOS SOBRE MARCADORES
BIOQUÍMICOS NA LESÃO MUSCULAR POR ESTIRAMENTO EM RATOS**

Dissertação apresentada ao Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica do Centro de Ciências Naturais e Exatas da Universidade Federal de Santa Maria (UFSM,RS), como requisito parcial para obtenção do grau de **Mestre em Ciências Biológicas: Bioquímica Toxicológica.**

Orientador: Profº. Dr. Gustavo Orione Puntel

**Santa Maria, RS, Brasil
2018**

Martins, Rodrigo
EFEITOS DOS RECURSOS TERAPÊUTICOS SOBRE MARCADORES
BIOQUÍMICOS NA LESÃO MUSCULAR POR ESTIRAMENTO EM RATOS /
Rodrigo Martins.- 2018.
72 p.; 30 cm

Orientador: Gustavo Orione Puntel
Coorientador: Félix Alexandre Antunes Soares
Dissertação (mestrado) - Universidade Federal de Santa
Maria, Centro de Ciências Naturais e Exatas, Programa de
Pós-Graduação em Ciências Biológicas: Bioquímica
Toxicológica, RS, 2018

1. Plasma Rico em Plaquetas 2. Imersão em água fria
3. dano oxidativo 4. Musculoesquelético I. Orione
Puntel, Gustavo II. Antunes Soares, Félix Alexandre
III. Título.

Sistema de geração automática de ficha catalográfica da UFSM. Dados fornecidos pelo autor(a). Sob supervisão da Direção da Divisão de Processos Técnicos da Biblioteca Central. Bibliotecária responsável Paula Schoenfeldt Patta CRB 10/1728.

Rodrigo Pereira Martins

**EFEITOS DOS RECURSOS TERAPÊUTICOS SOBRE MARCADORES
BIOQUÍMICOS NA LESÃO MUSCULAR POR ESTIRAMENTO EM RATOS**

Dissertação apresentada ao Programa de Pós-graduação em Ciências Biológicas: Bioquímica Toxicológica do Centro de Ciências Naturais e Exatas da Universidade Federal de Santa Maria (UFSM,RS), como requisito parcial para obtenção do grau de **Mestre em Ciências Biológicas: Bioquímica Toxicológica.**

Aprovado em 17 de agosto 2018:

Gustavo Orione Puntel, Dr. (UFSM)
(Presidente)

Luís Ulisses Signori, Dr.(UFSM)

Sara Marchesan de Oliveira, Dr^a.(UFSM)

Santa Maria, RS
2018

AGRADECIMENTOS

Em especial a minha MÃE meu PAI pelo amor, pelo incentivo, pela dedicação, pelos valores, além de ser um ponto de referência em minha vida são exemplos a serem seguidos.

A Carine Gazola, pelo seu amor, companheirismo, incentivo e paciência durante as minhas atividades do mestrado.

Ao meu orientador Prof. Gustavo Puntel acima de tudo pela oportunidade e confiança na realização de meus trabalhos, pelos conhecimentos transmitidos desde o começo da minha vida acadêmica até o momento. Admiro-o pelos seus conhecimentos, sua paciência e sua dedicação ao seu trabalho.

Aos colegas do laboratório do Prof. Félix, agradeço-os pela amizade, auxílio, compreensão, conhecimento e companheirismo compartilhados diariamente. Agradeço a todos por darem sentido a minha vida acadêmica desde os meus primeiros momentos na bioquímica.

Ao Prof. Felix Soares, agradeço pela co-orientação, por compartilhar os conhecimentos, pela disponibilidade de tempo, e também pelos “puxões de orelha” nos momentos certos. Além de minha gratidão, admiro-o por seu caráter e sua sabedoria.

Aos colegas de outros laboratórios e amigos da graduação que tomaram outros rumos, pelo companheirismo e amizade.

Aos professores e aos colegas do Programa de Pós-Graduação em Bioquímica Toxicológica, que de alguma maneira contribuíram para a minha formação científica.

Aos funcionários Elvadir e Rinaldo pela dedicação e competência com que realizam os seus trabalhos.

À Universidade Federal de Santa Maria e ao Programa de Pós-Graduação em Bioquímica Toxicológica pela possibilidade de realização deste curso.

A CAPES pela bolsa de estudos e pelos recursos financeiros concedidos durante os momentos iniciais deste curso.

Enfim, agradeço a todos que de alguma forma contribuíram para a realização deste trabalho.

RESUMO

Dissertação de mestrado

Universidade Federal de Santa Maria

Programa de Pós-graduação em Ciências Biológicas:

Bioquímica Toxicológica

EFEITOS DOS RECURSOS TERAPÊUTICOS SOBRE MARCADORES BIOQUÍMICOS NA LESÃO MUSCULAR POR ESTIRAMENTO EM RATOS

AUTOR: RODRIGO PEREIRA MARTINS

ORIENTADOR: GUSTAVO ORIONE PUNTEL

Data e Local da Defesa: Santa Maria, 17 de agosto de 2018.

A prática esportiva pode induzir lesões nas fibras musculares, gerando um dano oxidativo e um processo inflamatório. Práticas terapêuticas são utilizadas com o intuito de reduzir estes danos, como a injeção de plasma rico em plaquetas (PRP) e a imersão em água fria (CWI). Assim, o presente estudo teve como objetivo investigar através de biomarcadores a influência do tratamento com o frio terapêutico e/ou PRP em modelo de lesão muscular por estiramento em ratos. Métodos: Ratos machos *Wistar adultos* foram submetidos à lesão muscular por estiramento e imediatamente, os animais receberam uma aplicação intramuscular de PRP e/ou foram submetido a sessões de CWI. As análises bioquímicas como: Espécies reativas ao ácido tiobarbitúrico (TBARS), espécies reativas a diclorofluorescêina (DCFRS), grupos tiois (-SH), redução de MTT, glutathiona reduzida (GSH), glutaiona oxidada (GSSG), superóxido dismutase (SOD), catalase (CAT), mieloperoxidase (MPO), foram realizadas 1, 3, 5, 7 dias após o primeiro dia de tratamento. A lesão por estiramento no *gastrocnêmio* dos animais causou um aumento nos marcadores de dano oxidativo, tais como a formação de espécies reativas a diclorofluorescêina e peroxidação lipídica no músculo e no sangue. A combinação do tratamento com PRP e CWI parece ser o mais efetivo, em comparação aos tratamentos isolados, em prevenir o dano induzido pela lesão muscular possivelmente devido a sua capacidade em modular os danos à estrutura da célula muscular e também a intensidade da resposta inflamatória que segue a lesão músculo esquelética.

Palavras-chaves: Plasma Rico em Plaquetas, Imersão em água fria, dano oxidativo, Musculoesquelético.

ABSTRACT

Masters dissertation

Federal University of Santa Maria

Graduate Program in Biological Sciences:

Toxicological Biochemistry

EFFECTS OF THERAPEUTIC RESOURCES ON BIOCHEMICAL MARKERS IN INJURY STRETCH MUSCLE IN RATS

AUTHOR: RODRIGO PEREIRA MARTINS

ADVISOR: GUSTAVO ORIONE PUNTEL

Date and Location of Defense: Santa Maria, 17 of August 2018

The sports practice can induce injuries in the muscular fibers, generating an oxidative damage and inflammatory process. Therapeutic practices are used to reduce these damages, such as platelet-rich plasma (PRP) and cold water immersion (CWI). Thus, the present study aims to investigate through biomarkers the influence of treatment with CWI and / or PRP in muscle stretch model by stretching in rats. Methods: Adult male *Wistar* rats were subjected to stretch muscle injury and immediately, the animals received an intramuscular application of PRP and / or subjected to CWI. Biochemical analyzes such as: thiobarbituric acid reactive species (TBARS), dichlorofluorescein reactive species (DCFRS), thio groups (-SH), reduction of MTT, reduced glutathione (GSH), oxidized glutamine (GSSG), superoxide dismutase (SOD), catalase (CAT), myeloperoxidase (MPO), were performed 1, 3, 5, 7 days after the first day of treatment. Stretch lesion in the gastrocnemius of the animals caused an increase in the markers of oxidative damage, such as the formation of reactive species of dichlorofluorescein and lipid peroxidation in muscle and blood. Combined of PRP and CWI treatment appears to be the most effective in preventing muscle injury, compared to treatments isolated, possibly due to its ability to modulate damage to muscle cell structure and also the intensity of the inflammatory response following skeletal muscle injury.

Keywords: Platelet-rich plasma, cryotherapy, oxidative damage, musculoskeletal.

LISTA DE FIGURAS

Dissertação

Figura 1: Esquema ilustrativo demonstrando alguns danos causados pelo aumento das espécies reativas de oxigênio (EROs).....13

Manuscrito científico

Figura 1: Thiobarbituric acid reactive substances levels in muscle.....42

Figura 2: Oxidized dichlorofluorescein levels in muscle.....43

Figura 3: Methyl tetrazolium reduction levels in muscle.....44

Figura 4: Thiobarbituric acid reactive substances levels in erythrocytes.....,45

Figura 5: Myeloperoxidase enzyme activity.....,46

Figura 6: ratio GSH/GSSG in muscle.....,47

Figura 7: Non-protein thiol groups levels in muscle.....48

Figura 8: Antioxidant enzyme Superoxide Dismutase activity.....49

Figura 9: Antioxidant enzyme catalase activity.....50

LISTA DE ABREVEATURAS

ERs- Espécies reativas de oxigênio

ERO- Espécie reativa de oxigênio

O₂⁻- Ânions superóxido

OH⁻- Radicais hidroxila

H₂O₂- Peróxido de hidrogênio

HOCL- Ácido hipocloroso

O₂ – Oxigênio

SOD- Superóxido Dismutase

CAT- Catalase

GPx- Glutaiona Peroxidase

GSH- Glutationa reduzida

GSSG- Glutationa oxidada

AA- Ácido Ascórbico

NADPH- Nicotinamida-adenina-dinucleótido-fosfato-oxidase

EO- Estresse oxidativo

PRP- Plasma Rico em Plaquetas

PDGF- Fator de crescimento derivado de plaquetas (do inglês *Platelet-derived growth factor*)

TGF-β- Fator de crescimento transformante-β (do inglês *Transforming growth factor beta*)

VEGF- Fator de crescimento endotelial vascular (do inglês *Vascular endotelial growth factor*)

EGF- Fator de crescimento epidérmico (do inglês *Epidermal growth factor*)

FGF- Fator de crescimento de fibroblastos (do inglês *Fibroblast growth factor*)

HGF- Fator de crescimento de hepatócitos (do inglês *Hepatocyte growth factor*)

CWI – Imersão em água fria (do inglês *Cold water immersion*)

SUMÁRIO

1-	INTRODUÇÃO	8
1.1-	Lesão muscular	8
1.2-	Processo inflamatório e estresse oxidativo	10
1.3-	Plasma Rico em Plaquetas	14
1.4-	Crioterapia.....	16
1.5-	Justificativa.....	17
2-	OBJETIVO	18
3-	DESENVOLVIMENTO	19
	MANUSCRITO CIENTÍFICO.....	19
	COMBINED PLATELET-RICH PLASMA AND COLD WATER IMMERSION TREATMENT MINIMIZE THE DAMAGE FOLLOWING A SKELETAL MUSCLE STRETCH INJURY IN RATS.....	20
	ABSTRACT.....	21
	INTRODUCTION	22
	MATERIALS AND METHODS	24
	RESULTS	31
	DISCUSSION.....	33
	CONCLUSION.....	37
	DECLARATION OF INTEREST	37
	REFERENCES	38
4-	CONCLUSÃO.....	51
5-	PERPESCTIVAS	52
6-	REFERENCIAS BIBLIOGRÁFICAS	53

APRESENTAÇÃO

No item **INTRODUÇÃO**, está descrita uma sucinta revisão bibliográfica sobre os temas trabalhados nesta dissertação.

Os resultados que fazem parte desta dissertação estão apresentados sob a forma de um manuscrito científico, os quais se encontram alocado no item **MANUSCRITO CIENTÍFICO**. As seções Materiais e Métodos, Resultados, Discussão dos Resultados e Referências Bibliográficas, encontra-se no respectivo manuscrito e representa a íntegra deste estudo.

O item **CONCLUSÃO**, encontrado no final desta monografia, apresenta interpretações e comentários gerais sobre o manuscrito científico contido neste trabalho.

As **REFERÊNCIAS BIBLIOGRÁFICAS** se referem somente às citações que aparecem no item **INTRODUÇÃO** desta dissertação de mestrado.

1- INTRODUÇÃO

1.1- Lesão muscular

O músculo esquelético pode ser considerado um órgão composto de dois componentes principais, as fibras musculares e os tecidos envoltórios conjuntivos. As fibras musculares, com sua inervação, são responsáveis pela função contrátil do músculo, enquanto que o tecido conjuntivo fornece a estrutura que interliga as células musculares individuais durante a contração muscular e envolve os capilares e nervos no interior da estrutura muscular (BASSEL-DUBY & OLSON, 2006; JARVINEN et al., 2005).

Aproximadamente 45% da massa do corpo humano adulto é formado por tecido muscular. Em geral, os músculos desempenham um papel importante na locomoção, preensão, mastigação, movimentos oculares e outros eventos dinâmicos (OSTROVIDOV et al., 2013). O tecido muscular esquelético é composto por células que apresentam estabilidade como característica, em outras palavras, a morte destas células é relativamente rara e este evento é geralmente associado a lesões musculares (BASSEL-DUBY & OLSON, 2006).

As lesões musculares estão entre as mais comuns em diferentes tipos de esportes, a sua frequência variando entre 10-55% de todas as lesões. Neste contexto, é importante determinar qual o tipo e magnitude de lesão, sendo as contusões e os estiramentos musculares os mais frequentes. Entre essas lesões relacionadas ao esporte estão às lesões por estiramento, causadas quando indiretamente é produzida uma contração intensa combinada com o alongamento forte levando a um esforço excessivo ou estresse no musculoesquelético (PACHIONI et al., 2009). Em alguns casos, ocorre não somente o rompimento de fibras musculares, mas também um possível dano à estrutura óssea, sendo estas consideradas o tipo de lesão mais incomum na área esportiva (JARVINEN et al., 2005). A gravidade desses tipos de lesões musculares podem ser medidas pela incapacidade funcional do atleta para treinar e competir, e aumento do risco de lesões recorrentes. Em muitos casos, essa perda funcional pode durar de 30 a 40 dias (SÁNCHEZ et al., 2014).

A cura de um músculo esquelético lesionado segue um padrão constante, independentemente da causa subjacente. O processo do reparo tecidual apresenta-se dividido em três fases. Na 1ª fase ocorre a destruição/inflamação, caracterizada pela formação de hematoma, necrose e pelos sinais cardinais das reações inflamatórias (hipertermia, hiperemia, edema, dor e prejuízo/perda da função ou calor, rubor, tumor, dor e perda da função); na 2ª fase acontece o reparo, caracterizado pela fagocitose do tecido muscular necrosado, pela regeneração das miofibrilas, e pela proliferação de tecido conjuntivo cicatricial e de capilares sanguíneos; e na 3ª fase ocorre o remodelamento e reorganização do tecido, caracterizada pela maturação das miofibrilas regeneradas, pela contração e reorganização do tecido conjuntivo cicatricial, e pela restauração da funcionalidade do tecido muscular reparado (JARVINEN et al., 2005).

As lesões musculares já apresentadas podem ser divididas de acordo com sua magnitude, como, leve (1º grau), moderado (2º grau) e grave (3º grau) (JARVINEN et al., 2005). As lesões de 1º grau são as mais comuns e acontecem quando há um estiramento das fibras musculares, porém o indivíduo permanece praticando suas atividades. A sensação intensa de dor costuma aparecer no dia seguinte e o período de recuperação é de cerca de 5 dias. Nas lesões de 2º grau uma maior quantidade de fibra é rompida. Neste caso, é geralmente referida a sensação de que o músculo está “rasgando”, associada a incapacidade de manter a atividade física, sendo o período de recuperação corresponde a aproximadamente 10 dias. Já as lesões de 3º grau são os casos mais graves, nestes casos ocorre uma ruptura total da musculatura, geralmente na junção miotendínea, sendo o tempo de sua recuperação de, aproximadamente, 21 dias (KIRKENDALL & GARRETT, 2002).

1.2- Processo inflamatório e estresse oxidativo

Cada uma das fases da cura do tecido muscular apresenta uma íntima dependência do grau de lesão do tecido. Nestas circunstâncias, as propriedades de elasticidade, extensibilidade e contratibilidade das células musculares podem ser comprometidas. As alterações nas propriedades mecânicas e fisiológicas do tecido muscular podem ser resultado de uma incapacidade da unidade contrátil da fibra muscular, a qual é designada como sarcômero (JARVINEN et al., 2005).

A resposta inflamatória apresenta sintomas e sinais característicos, como a formação de calor, rubor, edema, dor e por último a perda da função. Em geral, o dano muscular é caracterizado por alterações do citoesqueleto dos miócitos, associada com uma perda da força e aumento da rigidez muscular, com o extravasamento de proteínas musculares, e com o processo inflamatório (GUILHEM et al., 2013). A resposta inflamatória subsequente à injúria muscular é necessária, e visa a reabilitação e regeneração tecidual.

As células inflamatórias são predominantemente neutrófilos e macrófagos, envolvidas na remoção do material danificado. Assim sendo, a fibra muscular pode responder à lesão tanto com a regeneração, quanto com a formação de fibrose na área lesada, caracterizando um processo inflamatório crônico. No entanto, este processo pode levar à inibição completa da regeneração do tecido muscular (JARVINEN et al., 2005).

O processo inflamatório em lesões musculares consiste de na quimiotaxia, na ativação e no acúmulo de neutrófilos dentro da área lesada (TOUMI & BEST, 2003). Os neutrófilos são extremamente importantes durante o processo inflamatório, sendo as primeiras populações de células brancas a entrar na área traumatizada ou tecidos estressados, e sua principal função é conter e destruir o tecido danificado ou corpos estranhos através da fagocitose (BROWN et al., 2001).

O processo inflamatório desencadeado para reabilitação frequentemente é acompanhada por um aumento da formação de Espécies Reativas (ERs), as quais auxiliam na degradação e remoção de células danificadas. Toda via, este processo deve ser controlado para evitar uma excessiva produção de ERs e infiltração de neutrófilos, as quais podem exacerbar o dano tecidual (TOUMI & BEST, 2003). Dentre as principais formas de ERs estão as derivadas do metabolismo oxidativo chamadas de Espécies Reativas de Oxigênio (EROs) (HALLIWELL & CROSS,

1994). Tendo em vista que o suprimento energético do tecido muscular é especialmente aeróbico, via fosforilação oxidativa mitocondrial, é possível compreender que o aumento na atividade metabólica muscular, tal qual é observada em lesões musculares, está geralmente associada com um aumento na formação de EROs (TOUMI & BEST, 2003).

O estresse oxidativo é a consequência de um desequilíbrio de pró-oxidantes e antioxidantes que levam a danos celulares e lesão tecidual. Quando as espécies reativas de oxigênio não são removidas de forma eficaz e com segurança, o estresse oxidativo pode prejudicar a saúde. A exaustão dos sistemas antioxidantes é uma das razões para a ocorrência do estresse oxidativo, o que resulta na produção excessiva de EROs ou radicais livres, como: ânions superóxido (O_2^-) e radicais hidroxila (OH^-). As espécies reativas de oxigênio também incluem compostos que não são radicais livres, como: H_2O_2 , ácido hipocloroso (HOCl) e ácido hipobromoso (HOBr). Estas espécies podem danificar as membranas lipídicas e produzir necrose celular (PUPPEL et al., 2014). Halliwell & Cross (1994) afirma que toxicidade por oxigênio (O_2) ocorre devido ao excesso de formação de radical O_2^- , sendo este, o produto de redução de um elétron de O_2 . Todos os organismos sofrem alguma exposição ao OH^- , pois este radical é gerado in vivo por fissão homolítica de títulos O-H na água. O Radical hidroxila é tão reativo com todas as moléculas biológicas que é impossível evoluir um para removedor específico de quase tudo dele em organismos vivos. Já o peróxido de hidrogênio é adicionalmente gerado in vivo por diversas enzimas oxidase, tais como glicolato oxidase, xantina oxidase e D-aminoácido oxidase (HALLIWELL & CROSS, 1994).

O processo inflamatório em lesões musculares consiste de neutrofilia, ativação de neutrófilos e acúmulo de neutrófilos dentro da área lesada (TOUMI & BEST, 2003). A presença de quantidades significativas de neutrófilos na área lesada determina a geração de ácido hipocloroso e hipoclorito ($HOCl/OCl^-$) a partir de H_2O_2 na presença de íons cloreto, a fim de promover a degradação e remoção do tecido danificado (BROWN et al., 2001).

Os dados experimentais mostram claramente que a remoção de O_2^- e H_2O_2 por sistemas de defesa antioxidante é essencial para a vida saudável aeróbica. A fim de neutralizar as ERs continuamente formadas durante o metabolismo aeróbico, os miócitos e células dispõem de vários mecanismos de defesa endógenos coletivamente definidos como antioxidantes. As duas classes principais destes

mecanismos antioxidantes celulares são: as defesa enzimática, em especial as enzimas Superóxido Dismutase (SOD), Catalase (CAT) e Glutathione Peroxidase (GPx); e as não-enzimáticas, em especial a Glutathione Reduzida (GSH) e o Ácido Ascórbico (AA). A enzima SOD contendo manganês no seu local ativo (Mn-SOD) nas mitocôndrias e SOD com cobre e zinco no sítio ativo (Cu, Zn-SOD) presente em grande parte no citosol, remove O_2^- e acelera muito a sua conversão ao H_2O_2 . A enzima Catalase converte H_2O_2 em água e O_2 , e ajuda a eliminar H_2O_2 gerado pelas enzimas peroxissomais. No entanto, enzima mais importante para remoção de H_2O_2 são as glutathione peroxidases (GPx), que necessitam de selênio (como um resíduo do sítio ativo da selenocisteína) para a sua ação. As enzimas GPx remove H_2O_2 , usando-o para oxidar GSH à glutathione oxidada (GSSG). A glutathione redutase é uma enzima flavoproteína, regenera de GSH a GSSG, com NADPH como uma fonte de poder redutor (HALLIWELL & CROSS, 1994).

O ácido ascórbico atua na fase aquosa como um excelente antioxidante sobre os radicais livres, mas não é capaz de agir nos compartimentos lipofílicos para inibir a peroxidação dos lipídeos. Por outro lado, estudos in vitro mostraram que essa vitamina na presença de metais de transição, tais como o ferro, pode atuar como uma molécula pró-oxidante e gerar os radicais H_2O_2 e OH^\cdot . Geralmente, esses metais estão disponíveis em quantidades muito limitadas e as propriedades antioxidantes dessa vitamina predominam in vivo (ODIN, 1997).

Sempre que a formação de ERs, em especial EROs, for além das capacidades antioxidantes celulares neutralizá-las, temos o desencadeamento de danos oxidativos a biomoléculas celulares. Esta situação é reconhecida como Estresse Oxidativo (EO), o qual vem sendo reconhecido como um evento fundamental na fisiopatologia de inúmeras doenças e também na fisiologia do envelhecimento humano. Dentre as principais alterações celulares associadas ao estresse oxidativo estão a peroxidação e comprometimento da permeabilidade de membranas lipídicas, as alterações nas funções enzimáticas, as alterações no funcionamento mitocondrial, e os comprometimentos na funcionalidade nuclear associada à síntese e renovação biomolecular, as quais podem resultar na necrose celular (HALLIWELL & CROSS, 1994).




Figura 1: Esquema ilustrativo demonstrando alguns danos causados pelo aumento das espécies reativas de oxigênio (EROs).

1.3- Plasma Rico em Plaquetas

Estudos ao longo do tempo investigam variáveis que influenciam a velocidade de cicatrização frente ao processo de reparação tecidual (DIMAURO et al., 2014; ANITUA et al., 2007) sendo que o uso de Plasma Rico em Plaquetas (PRP) é um recente e promissor método adjuvante nesse contexto. O objetivo do tratamento do PRP para a lesão muscular é o de melhorar e acelerar o processo de reparação muscular e, conseqüentemente, permitir que o paciente possa continuar com suas atividades desportivas ou diárias, o mais rapidamente possível, sem recaídas (SÁNCHEZ et al., 2014). O PRP é um método simples, derivado do processo laboratorial de sangue autógeno ou homólogo obtido através da centrifugação, de baixo custo e minimamente invasivo, que fornece um concentrado natural de fatores de crescimento obtido através de sangue que pode ser usado para melhorar a regeneração de um determinado tecido (KON et al., 2011).

Na literatura alguns estudos investigam a eficácia do PRP perante a aceleração do processo de regeneração tecidual (PRESTES et al., 2012; Sánchez et al., 2014). O PRP proporciona um aumento de 3 a 5 vezes na concentração de plaquetas quando comparada com a concentração normal no sangue (MARX, 2004) Após sua ativação, o PRP induz a produção/liberação de inúmeros tipos de fatores de crescimento para locais lesionados, incluindo o fator de crescimento derivado de plaquetas (PDGF), divididos em PDGF $\alpha\alpha$, PDGF $\beta\beta$ e PDGF $\alpha\beta$; fator de crescimento transformante- β (TGF- β), divididos em TGF- β 1 e TGF- β 2; fator de crescimento endotelial vascular (VEGF), fator de crescimento epidérmico (EGF), fator de crescimento semelhante a insulina-I (IGF-I), fator de crescimento de fibroblastos (FGF) e fator de crescimento de hepatócitos (HGF) (YUAN et al., 2012; MARX, 2001).

Produtos derivados de sangue autólogo transmitem além dos fatores de crescimento, citosinas e outras proteínas contidas nas plaquetas, assim como de fibrinogênio e outras proteínas plasmáticas, em um agregado biologicamente equilibrado. Estes podem ser responsáveis por duas características especiais: a resolução da inflamação e evitar a fibrose. Além de transmitir os fatores de crescimento, PRGF fornece ao tecido danificado um andaime de fibrina biológica transiente que deriva da polimerização de fibrinogênio, que é uma proteína do

sangue pleiotrópica que regula a coagulação, inflamação, e a regeneração de tecidos (SÁNCHEZ et al., 2014).

Relatos na literatura têm sugerido que os fatores de crescimento presentes nas plaquetas promovem uma potencialização da quimiotaxia, proliferação, diferenciação e secreção celular, podendo influenciar o tempo de reparação (BAUER et al., 2009).

Alguns estudos apresentaram bons resultados sobre os efeitos biológicos com uso do PRP em tecidos moles, como por exemplo, Anitua et al. (2007) que aborda um estudo randomizado para avaliar a eficácia e segurança do PRP para tratamento de úlceras cutâneas crônicas. Os seus resultados mostram que a porcentagem de área de superfície cicatrizada no grupo PRP foi significativamente maior do que no grupo de cuidados padrão durante todos os pontos de avaliação do estudo. De fato, a porcentagem da superfície cicatrizada em oito semanas foi 72,94% no PRP e 21,48% no grupo de tratamento padrão.

Há muito poucos dados sobre o efeito do PRP em lesões musculares. Um estudo recente utilizando um modelo de rato descobriu que o tratamento PRP resultou em um tempo de recuperação mais rápido de pequenas lesões musculares por esforços repetitivas (HAMMOND et al., 2009).

Em outro estudo com modelo de contusão em ratos, uma injeção local de PRP no músculo *gastrocnêmio* lesionado não resultou em diferenças significativas no resultado funcional em vários pontos da lesão, indicando que não há benefício provável para a cura. Além disso, não houve diferença significativa entre a administração de imediato ou tardio de PRP (DELOS et al., 2014).

1.4- Crioterapia

As práticas terapêuticas tem sido implementadas com o intuito de reduzir os danos sobre a musculatura esquelética, sendo uma delas a crioterapia (GUILHEM et al., 2013). A crioterapia é um dos tratamentos mais simples e mais antigos para a lesão muscular aguda, a qual anestesia a área a que se aplica e diminui o fluxo sanguíneo local e o metabolismo.

A crioterapia permanece como a modalidade terapêutica que apresenta uma grande frequência de utilização em situações de pós-lesão muscular esquelética, sendo muito aplicada por profissionais da área clínica desportiva. A grande aplicabilidade como medida terapêutica, é em função principalmente devido à sua ampla disponibilidade e baixo custo. Assim, atualmente muitos estudos descrevem a eficácia do frio usando modelos animais e também o sucesso desta modalidade terapêutica na prática desportiva para combater os efeitos posteriores a atividade física intensa e lesões musculares (BLEAKLEY et al., 2004; PUNTEL et al., 2011; MARTINS et al., 2015).

A utilização clínica da crioterapia em circunstâncias fisiopatológicas e/ou injúrias musculares, apresenta algumas características provenientes do resfriamento local, dentre essas, o efeito analgésico, a diminuição da demanda metabólica tecidual, uma redução do fluxo sanguíneo local em decorrência do efeito vasoconstritor e por atenuação da pressão hidrostática, a qual levaria a formação do edema (BLEAKLEY et al., 2004; SCHASER et al., 2007; PUNTEL et al., 2011).

Dentre os procedimentos utilizados, pode ser citada a Imersão em Água Fria (CWI), aplicada em condições variadas em relação à forma, tempo ou temperatura (PASTRE et al., 2009). De acordo com Almeida et al., (2016) a CWI é uma das estratégias de recuperação pós-esforço mais utilizadas no contexto esportivo e tem sido demonstrada um benefício na redução de marcadores de dano muscular. Entretanto, a literatura ainda é controversa quanto aos protocolos adotados, sobretudo com relação à temperatura da água, tempo e profundidade da imersão.

Neste contexto, o frio terapêutico mostra ser capaz de modular o dano oxidativo, possivelmente, pela sua capacidade de limitar a intensidade da resposta inflamatória, atenuar o comprometimento da função mitocondrial e também por preservar a morfologia do musculoesquelético. Isto pode ser explicado pelo fato da crioterapia atenuar a disfunção microvascular, diminuindo a temperatura, o

metabolismo e a demanda de O₂ na cadeia de transporte de elétrons. Além disso, é possível observar a preservação morfoanatômica e histológica do tecido lesado quando submetido ao tratamento com o frio (PUNTEL et al. 2011). Desta forma, o tratamento com Crioterapia, através do método de CWI, mostra um benefício e auxiliaria no processo de reabilitação do tecido lesado.

1.5- Justificativa

Alguns estudos investigam, de formas isoladas, a influência que o PRP e a CWI oferecem na reparação de tecidos musculoesqueléticos em diversos achados clínicos. No entanto, até o momento, nenhum estudo investigou as alterações bioquímicas determinadas pelo uso combinado destes recursos terapêuticos em modelos experimentais de lesões musculares.

Considerando o fato de existir poucos relatos na literatura sobre os fenômenos bioquímicos envolvidos nos efeitos do tratamento com PRP e CWI sobre a lesão musculoesquelética, o conhecimento de como estas técnicas exercem seus efeitos torna-se importante para o desenvolvimento de possíveis esclarecimentos sobre as mesmas, uma vez que estes constituem uma das estratégias mais utilizadas no tratamento de lesões musculares no âmbito esportivo.

2- OBJETIVO

2.1- Objetivo geral

O estudo teve como objetivo geral investigar através de experimentos bioquímicos a influência do tratamento com o banho de imersão em água fria e/ou Plasma rico em plaquetas em um modelo de lesão induzida por estiramento muscular em ratos.

2.2- Objetivo específico

- ✓ Avaliar os efeitos do modelo de estiramento muscular sobre marcadores bioquímicos de estresse oxidativo;
- ✓ Quantificar os níveis de substâncias reativas ao ácido tiobarbitúrico (TBARS) e de diclorofluoresceína oxidada (DCFRS) em amostras do tecido muscular e fração sanguínea dos animais submetidos à lesão e tratamentos;
- ✓ Analisar os níveis antioxidantes dos grupos tiois (-SH) e da glutatona reduzida (GSH) e oxidada (GSSG).
- ✓ Analisar os efeitos dos tratamentos sobre a atividade das enzimas superóxido dismutase (SOD) e catalase (CAT) em amostras do tecido muscular;
- ✓ Quantificar a resposta inflamatória no tecido muscular através da atividade enzimática da mieloperoxidase (MPO).

3- DESENVOLVIMENTO

MANUSCRITO CIENTÍFICO

Os resultados que fazem parte desta dissertação estão apresentados sob a forma de um manuscrito científico, no qual são apresentadas as seções Materiais e Métodos, Resultados, Discussão dos Resultados e Referências Bibliográficas relacionadas ao presente estudo. O manuscrito encontra-se na formatação de submissão para a revista científica *The American Journal of Sports Medicine*.

1 **COMBINED PLATELET-RICH PLASMA AND COLD WATER IMMERSION**
2 **TREATMENT MINIMIZE THE DAMAGE FOLLOWING A SKELETAL MUSCLE**
3 **STRETCH INJURY IN RATS.**

4

5 Rodrigo Pereira Martins¹; Diane Duarte Hartmann², Andrezza Bond Vieira Furtado²,
6 Bárbara Santos Luccas Duarte³, Felix Alexandre Antunes Soares⁴, Gustavo Orione
7 Puntel^{4*}.

8

91- 1- Master's student in biochemistry and toxicology the Federal University of Santa
10 Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.

112- 2- Doctoral student in biochemistry and toxicology the Federal University of Santa
12 Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.

133- 3- Master's student in rehabilitation physical motor the Federal University of Santa
14 Maria (UFSM), Santa Maria, Rio Grande do Sul, Brazil.

154- 4- Professor at the Federal University of Santa Maria (UFSM), Santa Maria, Rio
16 Grande do Sul, Brazil.

17 *Correspondent author

18 Gustavo Orione Puntel – Federal University of Santa Maria, UFSM – Campus Santa
19 Maria, Santa Maria, RS, Brasil

20 Phone: +55-XX-55-3220-8736

21 E-mail: gustavopuntel@yahoo.com.br

22

23

24

25

26

27

28

29

30

31

32

33

34 ABSTRACT

35

36 The skeletal muscle stretch injuries are commonly observed in sports. In order
37 to stimulate tissue healing, the platelet-rich plasma (PRP) and cold water immersion
38 (CWI) are widely used in clinical practice. This study investigated the effects of
39 isolated or combined PRP and/or CWI on the oxidative damage determined by a
40 stretch injury induced in *gastrocnemius* muscle of rats. PRP and CWI are applied
41 immediately after the injury, and the biochemical analysis was performed after 1, 3,
42 5, or 7 days. The levels of o thiobarbituric acid reactive substances and oxidized
43 dichlorofluorescein were significantly increased, both in skeletal muscle tissue and
44 erythrocytes preparations, and the combined PRP and CWI minimized these
45 parameters. Moreover, combined PRP and CWI were more effective than the
46 isolated treatments to increase catalase activity, also the ratio of reduced/oxidized
47 glutathione, and the non-protein thiols (-SH) group levels. In conclusion, we could
48 infer that the combination of these regular treatments used in an isolated form shows
49 a great potential for treatments of muscular injuries.

50

51

52

53

54

55

56

57

58

59 INTRODUCTION

60

61 Muscle injuries are common in different sports, affecting both professional and
62 amateur athletes, with their frequency varying to 55% of all sports lesions. These
63 muscle lesion result in the interruption of sports activity for the treatment, in this
64 sense, the greatest challenge of rehabilitation is to promote proper muscle tissue
65 repair in the shortest treatment period possible, enabling a quick return to the sport.
66 This being important both for athletes in order that they do not lose performance and
67 for amateurs so they do not stay away for prolonged periods from their healthy
68 habits. [11, 20]

69 Among these, the stretch injuries are indirectly resulted from a combination of
70 an intense contraction with a strong stretching, leading to an excessive stress on the
71 skeletal muscle tissue structure, as observed in an experimental study of Pachioni et
72 al., (2009) [22]. The mechanism of lesion consists on a vigorous contraction of the
73 skeletal muscle tissue when it is in a stretching position [19].

74 The inflammatory response that follows a muscle injury is essential for the
75 healing process and consequent tissue restructuring. This response is required to
76 start tissue regeneration via infiltration of neutrophils into the injured area. The
77 inflammatory process must be controlled to avoid an excessive production of reactive
78 oxygen species (ROS), such as superoxide anion (O_2^-) and hydrogen peroxide
79 (H_2O_2), which can exacerbate tissue damage leading to an increased lipid
80 peroxidation and even damage to DNA, resulting in an impaired intracellular
81 metabolism and even cellular death. [2 11, ,28, 32]

82 Therapeutic cold is a condition characterized by the diminution of tissue
83 temperature that is produced via different therapeutic modalities collectively
84 described as cryotherapy. The therapeutic cold is one simple and classic method

85 used to treat acute muscle injuries and its effects are related to a reduced sensitive
86 perception, such as nociception, and decreased blood flow and metabolism in treated
87 tissues. This therapeutic physical agent has been considered an effective tool to treat
88 different skeletal muscle lesions, based on its effects against the oxidative damage
89 [15, 25]. Immersion in cold water (CWI) is a common cryotherapy method used in the
90 treatment of skeletal muscle injuries that consist in submersion of the whole body or
91 part of them in cooled water for few minutes. CWI has been shown to reduce the
92 plasmatic markers of muscular damage and also to improve muscle contractile
93 properties. [15, 24]

94 On the other hand, the use of platelet-rich plasma (PRP) to treat skeletal
95 muscle injuries is recent and poorly described in the literature. PRP is derived from
96 autologous or heterologous, whole blood and contains numerous growth factors and
97 cytokines that have been shown to initiate and promote healing by stimulating cell
98 migration, cell proliferation, angiogenesis, and matrix synthesis. [35] In a previous
99 study of our group, we observed that PRP was able to modulate the oxidative
100 damage determined by a skeletal muscle contusion possibly by reducing the
101 impairment of myocytes mitochondrial function and improving their antioxidant
102 defense systems. [16] However, the mechanism by which PRP exerts these effects is
103 not fully understood.

104 Although both CWI and PRP show positive effects on treatment of
105 musculoskeletal lesion, there are no studies focusing its combined effects. Therefore,
106 the objective of this study was to evaluate the biochemical effects of treatment CWI
107 and/or PRP on the oxidative damage determined by a stretch injury in *gastrocnemius*
108 muscle of rats. In order to answer this question the levels of oxidative markers, such
109 as oxidized dichlorofluorescein (DCFOS) and thiobarbituric acid reactive substance

110 (TBARS), and also the index of cellular viability were analyzed. Moreover, enzymatic
111 antioxidants superoxide dismutase (SOD) and catalase (CAT) activities, and also
112 non-protein thiol groups (-SH) levels, the ratio of reduced glutathione (GSH) and
113 oxidized glutathione (GSSG) levels were determined. As an indicator of the
114 inflammatory response intensity, we measured myeloperoxidase (MPO) activity.

115

116

117 **MATERIALS AND METHODS**

118

119 **Ethical approval**

120 Animals were kept and used according to the institutional committee for animal
121 care and use of the Federal University of Santa Maria, Brazil, registered and
122 approved by the committee of ethics of animal use with the number
123 4694151216/2017 .

124

125 **Chemical reagents**

126 The thiobarbituric acid (TBA), Ellman (DTNB), N,N,N',N'-tetramethylbenzidine,
127 citric acid mono hydrate, calcium gluconate, 1-(4,5-Dimethylthiazol-2-yl)-3,5-
128 diphenylformazan, 2',7'-Dichlorodihydrofluorescein diacetate and o-phthalaldehyde
129 reagents were provided by Sigma-Aldrich Chemical Co. (St. Louis, MO). The others
130 were provided by local suppliers.

131

132 **Animals**

133 Seventy-two adult male Wistar rats, weighing 250–340 g, were placed (5
134 animals each cage) with food and water (ad libitum) in a temperature-controlled room

135 (22 ± 3°C) and at a ratio of 12 hours light/dark (lights were turned on by 7:00 am).

136 The animals were divided into four main groups:

137

138 (1) Control group: injured animals injected with one saline solution (NaCl 0.9%) at
139 every 48 h (50 µL, *i.m.*). The first injection was performed 2 h after injury (n = 18);

140 (2) PRP group: injured animals injected with PRP at every 48 h (50 µL, *i.m.*). The first
141 injection was performed 2 h after injury (n = 18). The choice for this PRP protocol
142 was based on previous studies.

143 (3) CWI group: injured animals submitted to CWI at every 24h (10°C ± 1°C, 10
144 minutes). The first session was performed 2 h after injury (n = 18);

145 (4) CWI+PRP group: injured animals submitted to CWI at every 24h (10°C ± 1°C, 10
146 minutes) and injected with PRP at every 48 h (50 µL, *i.m.*). The first injection and first
147 session CWI was performed 2 h after injury (n = 18);

148 The animals of each of these four groups were subdivided into further four
149 subgroups each (n = 4–5), according to the times where the analysis was performed
150 after the stretch injury (1, 3, 5, or 7 days). In all of these subgroups, the right hind
151 limb of the rats was submitted to skeletal muscle lesion and the left hind limb was
152 used as uninjured and untreated control.

153

154 **Skeletal muscle stretch injury**

155 The skeletal muscle stretch injury was performed according to Ozaki et al. [19]
156 with few modifications. Firstly, the animals were anesthetized with ketamine (50
157 mg/kg, ip) and xylazine (10 mg/kg, ip). After complete anesthetization, the animals
158 were placed in dorsal position to proceed with the right *gastrocnemius* muscle injury.
159 *Gastrocnemius* muscle was simultaneously stretching and submitted to tetanic

160 muscle contractions through an electrostimulatory device, with frequency of 50Hz,
161 twenty contractions of 10 seconds with intervals of 10 seconds are also performed
162 through self-adhesive electrodes. After the injury, the animals were left in the coop
163 until fully anesthesia recovery [19].

164

165 **PRP preparation**

166 PRP was prepared using a protocol that highest platelet concentration
167 according to Kaux et al. [12]. Briefly, the whole blood was first centrifuged at 180g for
168 10 min, then the supernatant fraction was removed and centrifuged again at 1000g
169 for 10 min. The final pellet containing the concentrated platelets fraction was
170 resuspended in 510 μL of S1 and activated with calcium gluconate 10%. The final
171 concentration of platelets obtained in PRP preparation used in this study was $4.905 \times$
172 10^3 platelets/ μL .

173

174 **Biochemical analysis**

175 The biochemical analyses were developed 1, 3, 5, and 7 days after lesion. The
176 rats were euthanized by anesthetic overdose and then decapitated. The
177 *gastrocnemius* muscles (from right and left legs) were dissected and kept in ice until
178 tissue preparation.

179

180 *Tissue preparation*

181 The *gastrocnemius* muscles were dissected, immediately homogenized in
182 saline solution (NaCl 0.9%) and kept in ice. After homogenization, the skeletal
183 muscle samples were centrifuged (at 2000g and 4°C for 10 min) in order to obtain a
184 slow-speed supernatant fraction (S1). The acquired S1 was used to measure

185 TBARS, DCFRS non-protein thiol(-SH) groups, and also to determine the CAT and
186 SOD enzymes activities. No fracture was observed in the dissected rat's legs.

187 The heparinized whole blood samples were precipitated with 40% TCA (1:1)
188 and centrifuged (2000g, at 4°C for 10 min) in order to obtain the supernatant fraction
189 (S2) that was used for the determination of TBA-RS and non-protein thiol (-SH)
190 groups.

191

192 *Measurement of oxidative stress markers*

193 *TBARS levels*

194 Thiobarbituric acid Reactive Substances (TBARS) levels, malondialdehyde
195 (MDA) mainly, were determined as an index of tissue lipid peroxidation according to
196 the method described by Ohkawa et al. [21] Aliquots of 500 µL of supernatant
197 fraction obtained after blood sample precipitation or 200 µL of skeletal muscle S1
198 were added to color reaction. TBA-RS levels were measured at 532 nm using a
199 standard curve of MDA and corrected by the protein content.

200

201 *DCFRS levels*

202 Oxidized dichlorofluorescein (DCFRS) levels were determined as an index of
203 the peroxide production by the cellular components. Skeletal muscle S1 samples (50
204 µL) were added to a medium containing a Tris-HCl buffer (0.01 mM; pH 7.4) and
205 DCFH-DA (7 µM). After DCFHDA addition, the medium was incubated in the dark for
206 1 h until fluorescence measurement procedure (excitation at 488 nm and emission at
207 525 nm and both slit widths used were at 5 nm). DCFRS levels were determined
208 using a standard curve of DCF and the results were corrected by the protein content
209 [23].

210

211 *MTT reduction levels*

212 Methyl-tetrazolium (MTT) reduction levels were determined as an index of the
213 dehydrogenase enzymes functions, which are involved in the cellular viability [4].
214 Aliquots of skeletal muscle S1 (500 μ L) were added to a medium containing 0.5
215 mg/mL of MTT and were incubated in the dark for 1 h at 37°C. The MTT reduction
216 reaction was stopped by the addition of 1 mL of dimethyl sulfoxide (DMSO). The
217 formed formazan levels were determined spectrophotometrically at 570 nm and the
218 results were corrected by the protein content [18].

219

220 *MPO enzyme activity levels*

221 The myeloperoxidase (MPO) enzyme activity was determined in skeletal
222 muscle S1 according to the method proposed by Grisham et al. [9], with some
223 modifications. Briefly, a sample of the skeletal muscle preparation (20 μ L) was added
224 to a medium containing potassium phosphate buffer (50 mM; pH = 6.0),
225 hexadecyltrimethylammonium bromide (0.5%), and N,N,N', N'-tetramethylbenzidine
226 (1.5 mM). The kinetic analysis of MPO was started after H₂O₂ (0.01%) addition and
227 the color reaction was measured at 655 nm at 37°C.

228

229 *Measurement of antioxidant markers*

230

231 *GSH and GSSG levels*

232 The measurement of reduced (GSH) and oxidized (GSSG) glutathione levels
233 was performed according to Hissin and Hilf (1976) [10] with few modifications. A
234 sample of skeletal muscle S1 (400 μ L) was added in a mean containing 200 μ L of

235 trichloroacetic acid (TCA 13%) was centrifuged (4 ° C at 13,000 rpm for 10 minutes).
236 For GSH measurement, 100 µL of the supernatant was diluted in 1,800 µL of the
237 phosphate buffer with EDTA (sodium phosphate (100 mM) and EDTA 5 mM), pH 8)
238 and 100 µL of O-phthalaldehyde (OPT 1 mg / mL). To measure GSSG, 250 µL of the
239 supernatant was incubated at room temperature with 100 µL of N-ethylmaleimide
240 (NEM 0.04 M) for 30 minutes at room temperature, after 140 µL of the mixture was
241 added to 1760 µL of the sodium hydroxide buffer (NaOH, 0.1 N), then 100 µL of OPT
242 was added.

243 The fluorescence measurement was analyzed at 420 nm emission wavelength
244 and 350 nm excitation and the results were expressed as GSH/GSSG ratio.

245

246

247 *Non-protein thiol (-SH) groups levels*

248 Non-protein (-SH) groups levels were determined in S1 skeletal muscle and
249 erythrocytes samples according to the method described by Ellman [7], with few
250 modifications. Firstly, the skeletal muscle S1 samples (1 mL) were precipitated with
251 TCA (5%, 0.5 mL) and centrifuged (at 2000g and 4°C, for 10 min), in order to obtain
252 the supernatant fraction S2.

253 Thereafter, samples of S2 fraction (500 µL) were added to a reaction medium
254 containing potassium phosphate buffer (TFK 0.25 mM, pH = 7.4) and DTNB (1 mM).
255 SH non-protein levels were measured by spectrophotometry at 412 nm. The
256 observed values were calculated according to a standard curve built with known GSH
257 concentrations and corrected by the protein content.

258

259

260 *CAT and SOD enzyme activities levels*

261 Catalase (CAT) enzyme activity was measured in the skeletal muscle S1
262 according to the method described by Aebi [1]. A sample of skeletal muscle S1 (50
263 mL) was added in a mean containing potassium phosphate buffer (TFK 50 mM, pH =
264 7.4) and H₂O₂ (1 mM). The CAT kinetic analysis was initiated after the H₂O₂
265 addition; the color reaction was measured at 240 nm.

266 Cytosolic superoxide dismutase (Cu/Zn SOD) enzyme activity was measured
267 in the skeletal muscle S1 according to the method described by Misra and Fridovich
268 [17]. Different samples of skeletal muscle S1 (10 to 50 µL) were added in a mean
269 containing glycine buffer (50 mM, pH = 10.5) and adrenaline (1 mM). The SOD
270 kinetic analysis was initiated after adrenaline addition; the color reaction was
271 measured at 480 nm.

272

273 *Protein measurement*

274 Protein content was measured according to the method described by Lowry et
275 al. [13] using bovine serum albumin as the standard measure.

276

277 *Statistical analysis*

278 All statistical analyses were done using the software GraphPad Prism 6.0 for
279 Windows. Data are expressed as mean and standard error, and differences between
280 groups were assessed by two-way ANOVA followed by Bonfferoni Post-Hoc test and
281 differences were considered significant when $p \leq 0.05$.

282

283

284

285 RESULTS

286

287 Oxidative damage markers analysis

288 Figures 1 and 2 show that the stretch lesion caused a significant increase in
289 TBARS ($p \leq 0.05$, Figure 1), and also DCFRS levels ($p \leq 0.05$ Figure 2) compared to
290 control conditions uninjured and untreated until the 3rd day of analysis. In both
291 analyses, the combined treatments (PRP and CWI) determined a reduction of
292 TBARS levels in comparison to lesion until de 5th day ($p \leq 0.05$, Figure 1), and the
293 DCFRS levels until de 7th day ($p \leq 0.05$, Figure 2); while the isolated PRP or CWI
294 treatments reduced TBARS and DCFRS levels only until de 3rd day of analysis
295 ($p \leq 0.05$, Figure 1 and 2, respectively).

296 The MTT reduction levels reached their lowest level on the 1st day after the
297 injury and were significantly lower than control values until the 3rd day after the injury
298 onset. Both the isolated or combined PRP and/or CWI treatments maintained the
299 MTT reduction values similar to control in all the time points analyzed, reaching
300 values significantly higher than the lesion group until the 3rd day after the lesion onset
301 ($p \leq 0.05$, Figure 3).

302 Further, then the increased lipid peroxidation in injured skeletal muscle tissue,
303 we observed a similar increase of TBARS levels in erythrocytes on the 1st day after
304 the stretch lesion onset, which was counteracted by PRP alone or CWI+PRP ($p \leq$
305 0.05 , Figure 4). In the lesion group, lipid peroxidation lasted until the 3rd day. The
306 combined CWI+PRP treatment significantly reduced the TBARS levels in comparison
307 to lesion condition during all the analyzed period ($p \leq 0.05$, Figure 4).

308

309

310

311 **MPO analysis**

312 The figure 5 shows the significant increase in skeletal muscle MPO enzyme
313 activity determined by the stretch lesion until the 3rd day ($p \leq 0.05$, Figure 5). Both
314 isolated and/or combined CWI and PRP treatments significantly reduced the MPO
315 enzyme activity in comparison to lesion condition in this period ($p \leq 0.05$, Figure 5).
316 Among the treatments, only the isolated CWI did not reach control uninjured and
317 untreated values in the 1st day after the lesion onset ($p \leq 0.05$, Figure 5).

318

319 **Antioxidant defense markers analysis**

320 The results show a significant reduction determined by the stretch lesion in the
321 skeletal muscle GSH / GSSG ratio until the 3rd day after the injury onset ($p \leq 0.05$,
322 Figure 6). Isolated CWI or combined CWI and PRP, in injured condition, determined
323 a significant increase in GSH / GSSG ratio in comparison to lesion untreated group
324 until the 7th day ($p \leq 0.05$, Figure 6). Furthermore, the combined CWI + PRP
325 increased the GSH / GSSG ratio in comparison to control uninjured and untreated
326 condition from the 3rd to the 5th day ($p \leq 0.05$, Figure 6).

327 Similar results were observed in the skeletal muscle non-protein (-SH) group
328 levels, where the stretch lesion determined a significant reduction until the 5th day
329 after the injury onset ($p \leq 0.05$, Figure 7). Both isolated and/or combined CWI and
330 PRP treatments increased the non-protein (-SH) group levels in comparison to lesion
331 untreated condition until the 5th ($p \leq 0.05$, Figure 7). Moreover, the combined CWI +
332 PRP increased the non-protein (-SH) group levels in comparison control uninjured
333 and untreated condition in the 5th day after the lesion onset ($p \leq 0.05$, Figure 7). The
334 non-protein (-SH) group levels in erythrocytes were not significantly different among
335 all tested conditions (data not show).

336 Figure 8 shows the SOD enzyme activity in the skeletal muscle after the
337 stretch injury. The isolated CWI treatment significantly decreased the SOD activity in
338 comparison to lesion group in the 1st day after the injury onset ($p \leq 0.05$, Figure 8).
339 Furthermore, the isolated CWI or the combined CWI + PRP treatments, in uninjured
340 conditions, significantly reduced the SOD activity in comparison to control uninjured
341 and untreated ($p \leq 0.05$, Figure 8). On the other hand, the isolated PRP treatment
342 increased the SOD activity in uninjured (5th day) or injured (from 3rd to 5th day)
343 conditions when compared to control uninjured and untreated ($p \leq 0.05$, Figure 8).

344 The stretch injury did not alter the enzymatic activity of CAT. However,
345 combined CWI + PRP treatment determined a significant increase in the skeletal
346 muscle CAT enzymatic activity in relation to lesion group during all the analyzed
347 period; and in comparison to control uninjured and untreated condition until the 3rd
348 day ($p \leq 0.05$, Figure 9). Moreover, the isolated PRP treatment increased CAT activity
349 in relation to lesion group until the 3rd day, and in comparison to control uninjured and
350 untreated condition only in the 3rd day after the lesion onset ($p \leq 0.05$, Figure 9).

351

352 **DISCUSSION**

353

354 Taken together, the results presented in this study show that the skeletal
355 muscle stretch injury determined a remarkable oxidative damage in both muscular
356 and blood tissues. This is in accordance with our previous findings, but presenting a
357 lower magnitude than that was observed after the experimental muscle contusion
358 [16].

359 Muscle stretch lesions are characterized by the rupture of sarcolemma, a
360 membrane responsible for muscle fibers structure maintenance. The damaged
361 muscle fibers undergo an inflammatory process and necrosis, been the neutrophils

362 the first inflammatory cells to reach the site of injury, followed by macrophages [22,
363 30]. The release by neutrophils, such as NADPH-oxidase and myeloperoxidase,
364 contribute to ROS generation, which is important to promote the destruction of
365 necrotic tissue. However, the excessive ROS (over the cellular antioxidant systems
366 capacity to scavenger them) could lead to an exacerbation of the inflammatory
367 process, determining damage to healthy myofibrils [30].

368 In this study, the separate CWI or PRP treatments determined a reduction in
369 the oxidative damage resulted from a skeletal muscle stretch injury, but the
370 combination CWI + PRP resulted in similar results but earlier than the isolated
371 treatments. Previous studies show that an excessive generation of ROS determined
372 by skeletal muscle injuries could extrapolate the site of the lesion and hence results
373 in oxidative damage of blood tissue components [16, 25]. Our results are in
374 accordance with this since we observed a significant increase in erythrocytes TBARS
375 levels after the onset of the stretch injury. The positive effects of isolated and/or
376 combined PRP and CWI treatment on erythrocyte lipid peroxidation were probably
377 due to the reduced oxidative damage at the site of lesion.

378 The analysis of MTT reduction is commonly used as an index of cellular
379 dehydrogenase activities, which are mainly located in the mitochondria, and
380 consequently reflects the cellular viability [3]. In fact, we observed here that the
381 stretch injury decreased the MTT reduction of the skeletal muscle preparation, which
382 is in agreement with previous observations [16]. The effects of isolated and/or
383 combined PRP and CWI treatment are probably related with a reduced skeletal
384 muscle mitochondrial dysfunction. One possible explanation for the better effects of
385 the combined CWI + PRP could be related to the independent and different

386 mechanism of action of PRP and CWI, especially in relation to their effect on the
387 cellular antioxidant systems activity.

388 In the present study, it was observed that the stretch lesion decreased both
389 GSH/GSSG ratio and thiols group levels in skeletal muscle tissue, but does not
390 change the antioxidant enzyme activities. In fact, CWI treatment maintained the
391 levels of non-enzymatic antioxidant (GSH/GSSG ratio and -SH levels) but decreased
392 the antioxidant enzymes activity Watanabe et al. (2016) described that the increase
393 of glutathione adducts stabilize hypoxia-inducible factors-1 α (HIF-1 α) during a
394 process of ischemia, determining a decrease of the ROS levels and also of the
395 enzymatic antioxidant activity [34]. Since cryotherapy is able to decrease local blood
396 flow and also ROS formation [15, 25], this pathway involving the
397 activation/stabilization of HIF-1 should be further studied after CWI application to
398 highlight this possible mechanism of action.

399 The treatment of muscle injuries with PRP has been shown to promote an
400 increase in growth factors release and also the improvement of contractile function in
401 the skeletal muscle tissue [6, 33]. Studies show that epidermal growth factor (EGF)
402 and platelet-derived growth factor (PDGF) activate tyrosine kinase, which leads to
403 phosphorylation of specific tyrosine residues and results in the activation of several
404 key signal transduction pathways, promoting cell proliferation and survival [28]. In this
405 study, the treatment with PRP determined an increase in the antioxidant activity of
406 SOD and CAT, which was also observed after a skeletal muscle contusion [16].
407 Tohidnezhad et al., (2014) shown that PRGF can activate the nuclear factor
408 erythroid-related factor 2 (NRF2) and demonstrated that this transcription factor plays
409 a complex role in of the function of the antioxidant system [31]. Normally NRF2
410 interacts with Kelch-like ECH-associated protein 1 (KEAP1), but in high ROS levels

411 conditions, these radicals oxidize cysteine residues sensitive on KEAP1 resulting in
412 dissociation of KEAP1 from NRF2. The NRF2 translocate to the nucleus and binds to
413 antioxidant-responsive elements (AREs) within the regulatory region of multiple
414 antioxidant genes. Thus, NRF2 directly affects the homeostasis of ROS by regulating
415 of the antioxidant defense systems through several mechanisms, such as induction
416 of catabolism of superoxides and peroxides [14].

417 The healing of skeletal muscle tissue involves a series of phases, which
418 include the acute inflammatory phase, an intermediate phase of repair, and the
419 advanced remodeling phase [5]. In the acute phase of skeletal muscle healing, an
420 extensive infiltration of inflammatory cells, predominantly neutrophils, is observed in
421 injured tissues. The MPO enzyme is found primarily in the azurophilic granules, but, it
422 has been established that a large percentage of them are from neutrophils. Similarly
423 to other studies [16, 25, 26], the MPO enzyme activity measurement in injured
424 tissues is a well-known indicator of the intensity of acute inflammatory response. In
425 the present study, we observed a significant increase in MPO activity in the lesion
426 group in comparison to the control group after 72 hours the stretch lesion. The
427 combined CWI + PRP treatment determined a decrease in MPO activity,
428 maintaining its level similar to the control. Furthermore, Tsai et al., (2018) observed
429 that the treatment with PRP decreased the presence of neutrophils after a stretch
430 injury, which may explain the decrease in the MPO enzymatic activity. However,
431 more studies are needed to explain the mechanisms by which neutrophil infiltration
432 decreases after treatment with PRP.

433 As observed in studies previous [25, 26, 27], we believe that the benefits of
434 cryotherapy are likely to be linked to its potential to modulate the intensity of the
435 inflammatory response that follows a skeletal muscle injury. Our results show that the

436 CWI treatment limited the significant increase in MPO activity, which is in accordance
437 with another study where cryotherapy reduced the inflammatory processes thought a
438 decrease in macrophage infiltration and a consequent reduction of TNF- α , NF- κ B,
439 TGF- β and MMP-9 mRNA levels [27]. It is believed that the effects of cryotherapy are
440 related to the physiological decrease in blood flow in the treated tissue, which may
441 determine a reduction in the intensity of the inflammatory response to an acute injury.
442 Moreover, the reduced blood flow could decreased oxygen metabolism in muscle
443 treated with cryotherapy, thus minimizing the secondary damage that follows an
444 acute injury [25, 26].

445

446 **CONCLUSION**

447

448 Our study can be considered a pioneer since it brings the combination of
449 treatments widely used in sports activity, but normally used separately. Our intention
450 was to perform an evaluation of the changes in oxidative stress marker levels
451 determined by CWI and PRP treatment after a skeletal muscle stretch lesion.
452 According to our results, we could infer that the combination of treatments shows a
453 great potential for treatments of muscular injuries. However, more studies are
454 needed to elucidate the effects of these treatments and to clarify possible
455 mechanisms by which they act on the musculoskeletal tissue.

456

457 **DECLARATION OF INTEREST**

458

459 All authors declare that they have no conflict of interest.

460

461 **ACKNOWLEDGEMENTS**

462 This work was supported by CAPS (CAPES/PROEX – Number of process
463 : 23038.005848/2018-31; Number of assist: 0737/2018) and CNPq.

464

465 **REFERENCES**

466

467

[1] Aebi H. Catalase in vitro. *Method Senzymol* 1984; 105:121–126.

468

469

[2] Alessio, H.M. Exercise-induce oxidative stress. *Medicine & Science in Sports & Exercise* 1999; 25:218-24.

470

471

[3] Berridge M, Tan A, Mccoy K, Wang R. The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. *Biochem* 1996; 4:14–19.

472

473

[4] Berna T, Dobrucki J. Mitochondrial and non-mitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1 and NAO mitochondrial.

474

475

[5] Borrione P, Fagnani F, Gianfrancesco A, Mancini A, Pigozzi F, Pitsiladis Y. The role of platelet-rich plasma in muscle healing. *Curr. Sports Med. Reports* 2017;

476

16:6, 459-463.

477

478

[6] Denapoli PMA, Stilhano RS, Ingham SJM, Abdala J. Platelet-Rich Plasma in a Murine Model: Leukocytes, Growth Factors, Flt-1, and Muscle Healing. *Am J Sports* 2016. DOI: 10.1177/0363546516646100

480

481

[7] Ellman GL. Tissue sulfhydryl groups. *Arch Biochem Biophys* 1952; 82:70–77.

482

483

[8] Goldfarb AH. Antioxidants: role of supplementation to prevent exercise-induced oxidative stress. *Med Sci Sports Exerc* 1993; 25:232–236.

484

485

[9] Grisham MB, Hernandez LA, Granger LN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. *Am J Physiol* 1986; 251:567–574.

486

487

[10] Hissin PJ, Hilf R. A fluorometric method for determination of oxidized and reduced glutathione in tissues. *Anal Biochem* 1976; 74(1):214–26.

488

489

[11] Jarvinen TAH, Jarvinen TLN, Kaariainen M. Biology of muscle trauma. *Am J Sports Med* 2005; 33:745–766

490 [12] Kaux JF, Golf CLe, Seidel L, Péters P, Gothot A, Albert A, Crielaarrd JM.
491 Étude comparative de cinq techniques de preparation plaquettaire (platelet-rich
492 plasma). *Pathologie Biologie* 2011; 59:157–160.

493 [13] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement
494 with the folin phenol reagent. *Biol Chem* 1951; 193:265–75.

495 [14] Ma Q. Role of Nrf2 in Oxidative Stress and Toxicity. *Annu Rev Pharmacol*
496 *Toxicol.* 2013 ; 53: 401–426.

497 [15] Martins CN, Moraes MB, Hauck M, Guerreiro LF, Rossato DD, Varela Jr
498 AS, da Rosa CE, Signori LU, Effects of cryotherapy combined with therapeutic
499 ultrasound on oxidative stress and tissue damage after musculoskeletal contusion in
500 rats, *Physiotherapy* 2015. DOI: [dx.doi.org/10.1016/j.physio.2015.10.013](https://doi.org/10.1016/j.physio.2015.10.013).

501 [16] Martins RP, Hartmann DD, Moraes JP, Soares FAA, Puntel GO. Platelet-
502 rich plasma reduces the oxidative damage determined by a skeletal muscle
503 contusion in rats. *Platelets* 2016; 27(8)784-790.

504 [17] Misra HP, Fridovich I. The role of superoxide anion in the auto oxidation of
505 epinephrine and a simple assay for superoxide dismutase. *J Biol Chem* 1972;
506 247:3170–3175.

507 [18] Mosmann T. Rapid colorimetric assay for cellular growth and survival:
508 application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983;16:55–
509 63.

510 [19] Ozaki, GAT; Camargo, R. C. T; Koike, T. E; Garcia, T. A; Castoldi, R. C;
511 Camargo, Filho J. C. S. Fractal analysis of skeletal muscle tissue of rats subjected to
512 stretch injury. *Int. J. Morphol* 2015; 33(3): 908-913.

513 [20] Ozaki GAT, Camargo RCT, Koike TE, Garcia TA, Castoldi RC, Pereira
514 JDAS, Constantino CJL, Camargo-Filho JCS. Analysis of photobiomodulation

515 associated or not with platelet-rich plasma on repair of muscle tissue by Raman
516 spectroscopy. *Lasers Med Sci*, 2016. DOI: 10.1007/s10103-016-2067-8

517 [21] Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues
518 by thiobarbituric acid reaction. *Anal Biochem* 1979; 95:351–358.

519 [22] Pachioni, S. C. A; Mazzer, N; Barbieri, C. E; DE Camargo, M. R;
520 Fregonesi, P. T. C. E; DO Carmo, E. M; Nozabielli, L. A. J; Martinelli, R. A.
521 Stretchinjuriesofskeletalmuscles: experimental study in rat soleus muscle. *Int.*
522 *J.Morphol.* 2009; 27(4):1139-1146.

523 [23] Pérez-Severiano F, Rodríguez-Pérez M, Pedraza-Chaverri J, Maldonado
524 PD, Medina-Campos ON, Ortiz-Plata A, Sánchez- García A, Villeda-Hernández J,
525 Gálvan-Arzate S, Aguilera P, Santamaría A. S-Allylcysteine, a garlic-derived
526 antioxidant, ameliorates quinolinic acid-induced neurotoxicity and oxidative damage
527 in rats. *Neurochem* 2004; 45:1175–1183.

528 [24] Pointon M, Duffield R. Cold water immersion recovery after simulated
529 collision sport exercise. *Med Sci Sports Exerc.* 2012; 44(2):206-16. DOI:
530 10.1249/MSS.0b013e31822b0977.

531 [25] Puntel GO, Carvalho NR, Amaral G, Lobato LD, Silveira SO, Daubermann
532 MF, Barbosa NV, Rocha JBT, Soares FAA. Therapeutic cold: Na effective kind to
533 modulate the oxidative damage resulting of a skeletal muscle contusion. *Free*
534 *Radical Res.* 2011, 45(2): 125-138.

535 [26] Puntel GO, Carvalho NR, Dobrachinski F, Salgueiro ACF, Puntel RL,
536 Folmer V, Barbosa NB, Royes LFF, Rocha JBT, Soares FAA. Cryotherapy reduces
537 skeletal muscle damage after ischemia/reperfusion in rats. *J. Anat* 2013; 222: 223-
538 230.

- 539 [27] Ramos GV, Pinheiro CM, Messa SP, Delfino GB, Marqueti RC, Salvini
540 TF, Durrigan JLQ. Cryotherapy reduces inflammatory response without altering
541 muscle regeneration process and extracellular matrix remodeling of rat muscle.
542 Scientific Reports 2016; 6:18525. DOI: 10.1038/srep18525
- 543 [28] Schieber M & Chandel N S. ROS function in redox signaling oxidative
544 stress. *Curr Biol.* 2014; 24(10): p453-62.
- 545 [29] Silva MAS, Carvalho TR, Cruz ACMB, Jesus LRG, Silva Neto LA, Trajano
546 ETL, Bezerra FS. Effect of time-dependent cryotherapy on redox balance of
547 quadriceps injuries. *Cryobiology*, 2016; 72: 1-6
- 548 [30] Souza J & Gottfried C. Muscle injury: Review of experimental models.
549 *Journal of Electromyography and Kinesiology* 2013; 1253–1260.
- 550 [31] Tohidnezhad M, Wruck CJ, Slowik A, Kweider N, Beckmann R, Bayer A,
551 Houben A, Brandenburg L O, Varoga D, Sönmez TT, Stoffel M, Jahr H, Lippross S,
552 Pufe T. Role of platelet-released growth factors in detoxification of reactive oxygen
553 species in osteoblasts. *Bone* 2014; 65:9–17.
- 554 [32] Toumi, H; Best, T M. The inflammatory response: friend or enemy for
555 muscle injury? *Br J Sports Med.* 2003; 37:4, 284-6.
- 556 [33] Tsai WC, Yu TY, Chang GJ, Lin LP, Lin MS, Pang JHS. Platelet-Rich
557 Plasma Releasate Promotes Regeneration and Decreases Inflammation and
558 Apoptosis of Injured Skeletal Muscle. *Am J Sports Med.* 2018; 1–7. DOI:
559 10.1177/0363546518771076.
- 560 [34] Watanabe Y, Murdoch CE, Sano S, Ido Y, Bachschmid MM, Cohen RA,
561 Matsui R. Glutathione adducts induced by ischemia and deletion of glutaredoxin-1
562 stabilize HIF-1 α and improve limb revascularization. *PNAS* 2016; 113:21, 6011–
563 6016.


564 [35] Zhang JY, Fabricant PD, Ishmael CR, Wang JC, Petrigliano FA, Jones
 565 KJ. Utilization of Platelet-Rich Plasma for Musculoskeletal Injuries. The Orthopaedic
 566 J Sports Med. 2016; 4:12.

567

568 FIGURES

569

570 **Figure 1**




571

572 **Figure 1:** Isolated or combine PRP and/or CWI effects on the stretch injury-induced oxidative damage
 573 throughout time (1, 3, 5 and 7 days after injury) assessed by means of the MDA levels and expressed in
 574 percentage of control value. Values are presented as mean \pm SEM and were analyzed by ANOVA (two-away),
 575 followed by Bonferroni test. Differences were considered significant when $P < 0.05$. * = differences found
 576 between the control of their day without injury. # = significant difference found in comparison to the lesion
 577 group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group.


578

579 **Figure 2**




580 **Figure 2:** Isolated or combine PRP and/or CWI effects on the stretch injury-induced oxidative damage
 581 throughout time (1, 3, 5 and 7 days after injury) assessed by means of the DCFRS levels and expressed in
 582 percentage of control value. Values are presented as mean ± SEM and were analyzed by ANOVA (two-away),
 583 followed by Bonferroni test. Differences were considered significant when $P < 0.05$. * = differences found
 584 between the control of their day without injury. # = significant difference found in comparison to the lesion
 585 group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group.
 586
 587

588 **Figure 3**




589 **Figure 3:** Isolated or combine PRP and/or CWI effects on the stretch injury-induced oxidative damage
 590 throughout time (1, 3, 5 and 7 days after injury) assessed by means of the MTT reduction levels expressed in
 591 percentage of control value. Values are presented as mean ± SEM and were analyzed by ANOVA (two-away),
 592 followed by Bonferroni test. Differences were considered significant when P < 0.05. * = differences found
 593 between the control of their day without injury. # = significant difference found in comparison to the lesion
 594 group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group.
 595
 596

597 **Figure 4**


598
 599
 600
 601
 602
 603
 604
 605

Figure 4: Isolated or combine PRP and/or CWI effects on the stretch injury-induced oxidative damage throughout time (1, 3, 5 and 7 days after injury) assessed by means of the MDA levels and expressed in percentage of control value. Values are presented as mean \pm SEM and were analyzed by ANOVA (two-away), followed by Bonferroni test. Differences were considered significant when $P < 0.05$. * = differences found between the control of their day without injury. # = significant difference found in comparison to the lesion group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group.

606 **Figure 5**



607
 608 **Figure 5:** Isolated or combine PRP and/or CWI effects on the stretch injury-induced MPO enzyme activity
 609 throughout time (1, 3, 5 and 7 days after injury) assessed by means of the delta absorbance/mg of protein. Values
 610 are presented as mean ± SEM and were analyzed by ANOVA (two-away), followed by Bonferroni test.
 611 Differences were considered significant when P < 0.05. * = differences found between the control of their day
 612 without injury. # = significant difference found in comparison to the lesion group. \$ = significant difference
 613 found in comparison to lesion + CWI + PRP group. N= 5/group.
 614

615 **Figure 6**

616

617

618

619


620

621

622

623

Figure 6: Isolated or combine PRP and/or CWI effects on the stretch injury-induced oxidative damage throughout time (1, 3, 5 and 7 days after injury) assessed by means of the GSH/GSSG ratio. Values are presented as mean \pm SEM and were analyzed by ANOVA (two-away), followed by Bonferroni test. Differences were considered significant when $P < 0.05$. * = differences found between the control of their day without injury. # = significant difference found in comparison to the lesion group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group

624 **Figure 7**

625

626

627

628

629


630

631


632

Figure 7: Isolated or combine PRP and/or CWI effects on the stretch injury-induced oxidative damage throughout time (1, 3, 5 and 7 days after injury) assessed by means of the SH levels and expressed in percentage of control value. Values are presented as mean \pm SEM and were analyzed by ANOVA (two-away), followed by Bonferroni test. Differences were considered significant when $P < 0.05$. * = differences found between the control of their day without injury. # = significant difference found in comparison to the lesion group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group

633 **Figure 8**



634
 635 **Figure 8:** Isolated or combine PRP and/or CWI effects on the stretch injury-induced SOD enzyme activity
 636 throughout time (1, 3, 5 and 7 days after injury) assessed by means of the SOD units levels and expressed in
 637 percentage of control value. Values are presented as mean ± SEM and were analyzed by ANOVA (two-away),
 638 followed by Bonferroni test. Differences were considered significant when P < 0.05. * = differences found
 639 between the control of their day without injury. # = significant difference found in comparison to the lesion
 640 group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group.
 641

642 **Figure 9**

643

644

645

646

647

648

649

Figure 9: Isolated or combine PRP and/or CWI effects on the stretch injury-induced CAT enzyme activity throughout time (1, 3, 5 and 7 days after injury) assessed by means of the H₂O₂/min/mg prot. and expressed in percentage of control value. Values are presented as mean \pm SEM and were analyzed by ANOVA (two-away), followed by Bonferroni test. Differences were considered significant when $P < 0.05$. * = differences found between the control of their day without injury. # = significant difference found in comparison to the lesion group. \$ = significant difference found in comparison to lesion + CWI + PRP group. N= 5/group

4- CONCLUSÃO

A utilização dos recursos terapêuticos como o CWI e o PRP demonstrou ser eficientes no tratamento do estiramento muscular. A lesão muscular esquelética provocada pelo estiramento aumentou os marcadores de dano oxidativo. Além disso, a intensidade da resposta inflamatória parece ser também um fator envolvido na gênese do dano oxidativo nos momentos que sucedem a lesão muscular esquelética por estiramento. A aplicação terapêutica combinada entre CWI e PRP reduz o dano oxidativo, preserva a capacidade antioxidante e apresenta um efeito modulatório sobre a resposta inflamatória auxiliando na recuperação do tecido musculoesquelético.

5- PERSPECTIVAS

Tendo em vista os resultados obtidos neste trabalho, as perspectivas para trabalhos posteriores são:

- ✓ Avaliar o efeito da combinação dos tratamentos com CWI e PRP sobre parâmetros comportamentais e funcionais nos ratos submetidos à lesão muscular;

- ✓ Investigar a participação de mediadores químicos pro e anti-inflamatórios, tais como interleucinas e fatores de transcrição do sistema antioxidante, durante o período da lesão muscular, assim como o efeito dos tratamentos sobre estes fatores.

6- REFERENCIAS BIBLIOGRÁFICAS

. ALMEIDA AC, MACHADO AF, ALBUQUERQUE MC, NETTO LM, VANDERLEI FM, VANDERLEI LC. The effects of cold water immersion with different dosages (duration and temperature variations) on heart rate variability post-exercise recovery: a randomized controlled trial. **J Sci Med Sport.**;19(8):676-81; 2016.

ANITUA E. Effectiveness of autologus preparation rich in growth factors for the treatment of chronic cutaneous ulcers. **Journal of Biomedical Materials Research Part B: Applied Biomaterials.** v.10.p.100-12/jbmb; 2007.

BASSEL-DUBY, R; OLSON, E. N. Signaling pathways in skeletal muscle remodeling. **Annu Rev Biochem**,75, 19-37; 2006.

BAUER, J A. CORREA, L. LIMA, F L M. LIMA, L A P A. PUSTIGLIONI, F E. Efeitos do plasma rico em plaquetas no processo de reparação de feridas dérmicas padronizadas em ratos. **Rev. Periodontia.** v.19(3): p.98-108; 2009.

BROWN, K E. BRUNT, E M. HEINECKE, J W. Immunohistochemical detection of myeloperoxidase and its oxidation products in kupffer cells of human liver. **Rev. Am J Pathol.** v.159, p. 2081-8; 2001.

BLEAKLEY, C.; MCDONOUGH, S.; MACAULEY, D. The use of ice in the treatment of acute soft-tissue injury: a systematic review of randomized controlled trials. **Am J Sports Med**, v. 32, n. 1, p. 251-61, Jan-Feb 2004.

CHAPPLE, S. J; SIOW, R. C. M; MANN, G. E. Crosstalk between Nrf2 and the proteasome: Therapeutic potential of Nrf2 inducers in vascular disease and aging. **Inter. J Bioch. & Cell Biology**, 44, 1315–1320; 2012.

DELOS, D. LEINWEBER, M J. CHAUDHUR, S. ALZOOBAEE, S. GAO, YINGXIN. RODEO, S A.The effect of Platelet-Rich Plasma on Muscle Contusion Healing in a Rat Model. **Am. Jour. Of Sports Med.** V. 42 nº 9; 2014

DIMAURO, I. GRASSO, L. FITTIPALDI, S. FANTINI, C. MERCATELLI, N. RACCA, S. GEUNA, S. GIANFRANCESCO, A. CAPOROSI, D. PIGOZZI, F. BORRIONE, P. Platelet-Rich Plasma and Skeletal Muscle Healing: A Molecular Analysis of the Phases of the Regeneration Process in an Experimental Animal Model. **Plos one**. v.9; 2014.

GUILHEM, G; HUG, F; COUTURIER, A; REGNAULT, S; BOURNAT, L; FILIARD, JR; DOREL, S. Effects of Air-Pulsed Cryotherapy on Neuromuscular Recovery Subsequent to Exercise-Induced Muscle Damage. **Am J Sports Med**, 41:1942 published online June, 2013.

HALLIWELL, B.; CROSS, C. E. Oxygen-derived species: the irrelation to human disease an denviron mental stress. **Environ Health Perspect**, v. 102 (10), p. 512, Dec 1994.

HAMMOND JW, HINTON RY, CURL LA, MURIEL JM, LOVERING RM. Use of autologous platelet-rich plasma to treat muscle strain injuries. **Am J Sports Med**. v.37(6): p.1135-42; 2009.

HENSEL, P; PERRONI, M. G; LEAL JUNIOR, E. C. P. Musculoskeletal injuries in athletes of the 2006 season's brazilian women's speed canoeing team. **Acta ortop bras** 16-4: 233-237; 2008.

IVANOV AR, NAZIMOV IV, BARATOVA L. Detemination of biologically active low-molecular-mass thils in human blood. **J Chromat**; 895: 157-66; 2000.

JARVINEN TAH, JARVINEN TLN, KAARIAINEN M. Biology of muscle trauma. **Am J Sports Med**; v.33: p.745–766; 2005.

KAUX, J. F; GOLF, C; L; E; SEIDEL, L; PÉTERS, P; GOTHOT, A; ALBERT, A; CRIELAARRD, J. M. Étude comparative de cinq techniques de preparation plaquettaire (platelet-rich plasma). **Pathologie Biologie**, 59:157–160; 2011.

KON, E; FILARDO, G; DI MARTINO, A; MARCACCI, M. Platelet-rich plasma (PRP) to treat sports injuries: evidence to support its use. **Knee Surg Sports Traumatol Arthrosc.** v.19 (4): p.516-27, 2011.

MARX, R E. Platelet-rich plasma (PRP): what is PRP and what is not PRP? **Implant Dent.** v.10: p.225–28, 2001.

MARX RE. Platelet-rich plasma: evidence to support its use. **J Oral Maxillofac Surg.** v.62: p.489-96; 2004.

LEE, S; KIM, M; LIM, W; KIM, T; KANG, C. Strenuous exercise induces mitochondrial damage in skeletal muscle of old mice. **Bioch. and Bioph. Res. Commu.** 461: 354- 360; 2015.

MARTINS, C. N; MORAES, M. B; HAUCK, M; GUERREIRO, L. F; ROSSATO, D. D; VARELA, JR. A. S; ROSA, C. E; SIGNORI, L. U. Effects of cryotherapy combined with therapeutic ultrasound on oxidative stress and tissue damage after musculoskeletal contusion in rats. **Physio**, 2015.

MOHR, M; THOMASSEN, M; GIRARD, O; RACINAIS, S; NYBO, L. Muscle variables of importance for physiological performance in competitive football. **Eur J Appl Physiol, Octu**; 2015.

MOLDOVEANU, A. I; SHEPHARD, R. J; SHEK, P. N. The cytokine response to physical activity and training. **Sports Med**; 31:115-44; 2001.

NIEMAND, C; NIMMESGERN, A; HAAN, S; FISCHER, P; SCHAPER, F; ROSSAINT, R; HEINRICH, P. C; MULLER-NEWN, G. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. **Jour. Immunology**, 170:3263-3272; 2003

NIKOLAOU, P. K; MACDONALD, B; L; GLISSON, R. R; SEABER, A. V; GARRET, W. E. JR. Biomechanical and histological evaluation of muscle after controlled strain injury. **Am J Sports Med**;15(1):9–14.20; 1987.

ODIN, A.P. Vitamins as ant mutagens: advantages and some possible mechanisms of antimutagenicaction. **Mutation Research**, Amsterdam, v.386, n.1, p.39-67, 1997.

OSTROVIDOV, S. HOSSEINI, V. AHADIAN, S.FUJIE, T. PARTHIBAN, S P. RAMALINGAM, M. BAER,H.KAJI, H. KHADEMHOSEINI, A. Skeletal muscle tissue engineering: Methods to form skeletal myotubes and their applications. **TEB**. v10: p.05-34. 2013

OZAKI, G; CAMARGO, R. C. T; KOIKE, T. E; GARCIA, T. A; CASTOLDI, R. C; CAMARGO, FILHO J. C. S. Fractal analysis of skeletal muscle tissue of rats subjected to stretch injury. **Int. J. Morphol** 33(3): 908-913; 2015.

PACHIONI, S. C. A; MAZZER, N; BARBIERI, C. E; DE CAMARGO, M. R; FREGONESI, P. T. C. E; DO CARMO, E. M; NOZABIELLI, L. A. J; MARTINELLI, R. A. Stretch injuries of skeletal muscles: experimental study in rats soleus muscle. **Int. J. Morphol.**, 27(4):1139-1146; 2009.

PASTRE CM, BASTOS FDN, NETTO JÚNIOR J, VANDERLEI LCM, HOSHI RA. Métodos de recuperação pós-exercício: uma revisão sistemática. **Rev Bras Med Esporte**. 15:138-44; 2009.

PETERSEN, A. M. W; PEDERSEN, B. K. The anti-inflammatory effect of exercise. **J Appl Physiol**, 98:1154-62; 2005.

PUNDUK, Z; ORAL, O; OZKAYIN, N; RAHMAN, K; VAROL, R. Single dose intra-muscular platelet rich plasma reverses the increase in plasma iron levels in exercise-induced muscle damage: A pilot study. **J Sport and Health Science** xx, 1-6; 2015.

PUNTEL, G. O; CARVALHO, N. R; AMARAL, G. P; LOBATO, L. D; SILVEIRA, S. O; DAUBERMANN, M. F; BARBOSA, N. V; ROCHA, J. B. T; SOARES, F. A. A.

Therapeutic cold: An effective kind to modulate the oxidative damage resulting of a skeletal muscle contusion. **Free Radical Research**, February 45(2): 125–138. 2011.

PUPPEL, K. KAPUSTA, A. KUCZYNSKA, B. The etiology of oxifative stress in the various species of animals, a review. **Rev.J Sc iFood Agric**. doi:10.1002/jsfa.7015; 2014.

SÁNCHEZ, M. ANITUA, E. DELGADO, D. SÁNCHEZ, P. ORIVE, G. PADILLA, S. Muscle repair: platelet-rich plasma derivates as a bridge from spontaneity to intervention. **Rev. injury int**. v. 45 p.7-14; 2014.

SILVA, E; MALDONADO, I. R. S. C; MATTA, S. L. P; MAIA, G. C; BOZI, L. H. M; SILVA, K. A; CASTRO, C. A; NATALI, A. J. Treinamento em natação com baixa intensidade não Protege músculo esquelético contra lesões Induzidas por exercício exaustivo em ratos. **Rev Bras Med Esporte**, 17: 3; 2011

SILVEIRA, P. C. L; SILVA, L. A; DAIANE, F. B; FREITAS, T. P; STRECK, E. L; PINHO, R. Evaluation of mitochondrial respiratory chain activity in muscle healing by low-level laser therapy. **J Photoch. and Photobiology B: Biology** 95:89–92; 2009.

TAKAYA, K, SUZUKI, T; MOTOHASHI, H; ONODERA, K; SATOMI, S; KENSLER, T. W; YAMAMOTO, M. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. **Free Radical Biology and Medicine**, 53: 817–827; 2012.

TERADA, S; YOKOZEKI, T; KAWANAKA, K; OGAWA, K; HIGUCHI, M; EZAKI, O; TABATA, I. Effects of high-intensity swimming training on GLUT-4 and glucose transport activity in rat skeletal muscle. **J Appl Physiol** 90: 2019-2024; 2001.

TOUMI, H; BEST, T M. The inflammatory response: friend or enemy for muscle injury? **Br J Sports Med**, 37:4, 284-6; 2003.

WARBOYS, C. M; AMINI, N; DE LUCA, A; EVANS, P. C. The role of blood flow in determining the sites of atherosclerotic plaques. **Medicine Reports**, 3:5, 1-8, 2011.

Yuan T. Guo, S C. Han, P. Zhang, C Q. Zeng, BF. Applications of leukocyte- and platelet-rich plasma (L-PRP) in trauma surgery. **Curr Pharm Biotechnol**. v.13: p.1173-84; 2012.

ANEXOS

ANEXO A: Registro no Gabinete de Projetos

10/08/2018

Portal de Projetos - Visualizar projeto

Visualizar projeto

Dados Básicos

Título EFETOS DO PLASMA RICO EM PLAQUETAS SOBRE AS ALTERAÇÕES BIOQUÍMICAS E MORFOLÓGICAS INDUZIDAS POR LESÕES MUSCULARES EM RATOS			
Número do projeto 037285		Número do processo 037285	
Classificação principal Pesquisa	Data inicial 01/05/2014	Data final 31/07/2018	
Resumo Aproximadamente 45% da massa do corpo humano adulto é formado por tecido muscular. As lesões musculares estão entre as mais comuns em diferentes tipos de esportes, sendo a sua frequência variando entre 10-55% de todas as lesões. Estudos ao longo do tempo investigam variáveis que influenciam a velocidade de cicatrização frente ao processo de reparação tecidual, sendo que o uso de plasma rico em plaquetas (PRP) é um recente e promissor método adjuvante nesse contexto. Com isso, este estudo tem como objetivo avaliar os efeitos do PRP sobre as alterações bioquímicas e morfológicas induzidas por um modelo de lesão muscular em ratos. Para a realização deste estudo serão utilizados ratos wistar, divididos em 2 grupos: grupo GC (controle), grupo GPRP (PRP). As análises experimentais bioquímicas e morfológicas serão realizadas em diferentes momentos após o desenvolvimento da lesão. A partir de amostras de tecido muscular e sanguíneo, a fim de investigar a evolução cronológica das lesões bem como verificar a eficácia do tratamento com PRP.			
Observação [Não informado]			
Projeto em âmbito confidencial Não		Projeto superior -	
Palavra-chave 1 plasma rico em plaquetas	Palavra-chave 2 lesões musculares	Palavra-chave 3 [Não informado]	Palavra-chave 4 [Não informado]
Tipo de evento Não se aplica		Carga horária do curso [Não informado]	
Situação Em andamento		Avaliação Não avaliado	Última avaliação 07/04/2017

Gestão do conhecimento e gestão financeira

O projeto pode gerar conhecimento passível de proteção? Não		
Propriedade Intelectual [Não informado]	Proteção Especial [Não informado]	Direito Autoral - Copyright Não
O projeto contrata uma fundação? Indique a fundação Não necessita contratar fundação		

Classificações

Tipo	Classificação
Classificação CNPq	2.00.00.00-8 CIÊNCIAS BIOLÓGICAS
Linha de pesquisa	02.00.00 SAUDE
Quanto ao tipo de projeto de pesquisa	2.01 Projeto de Pesquisa Pura
Nenhum objetivo estratégico indicado	

Participantes

Matrícula	Nome	Função	Carga Horária	Período
-----------	------	--------	---------------	---------

<https://portal.ufsm.br/projetos/participante/meusprojetos/View.html?IdProjeto=45709>

1/3

ANEXO B: APROVAÇÃO DO COMITÊ DE ÉTICA EM EXPERIMENTAÇÃO ANIMAL – UFSM



Comissão de Ética no Uso de Animais

da Universidade Federal de Santa Maria

CERTIFICADO

Certificamos que a proposta intitulada "Efeitos dos recursos terapêuticos sobre as alterações bioquímicas e moleculares nas lesões musculoesqueléticas em ratos", protocolada sob o CEUA nº 4694151216, sob a responsabilidade de **Gustavo Orione Puntel e equipe; Rodrigo Pereira Martins** - que envolve a produção, manutenção e/ou utilização de animais pertencentes ao filo Chordata, subfilo Vertebrata (exceto o homem), para fins de pesquisa científica ou ensino - está de acordo com os preceitos da Lei 11.794 de 8 de outubro de 2008, com o Decreto 6.899 de 15 de julho de 2009, bem como com as normas editadas pelo Conselho Nacional de Controle da Experimentação Animal (CONCEA), e foi **aprovada** pela Comissão de Ética no Uso de Animais da Universidade Federal de Santa Maria (CEUA/UFSM) na reunião de 23/03/2017.

We certify that the proposal "Effects of therapeutic resources on biochemical and molecular changes in musculoskeletal injuries in rats", utilizing 160 Heterogenics rats (160 males), protocol number CEUA 4694151216, under the responsibility of **Gustavo Orione Puntel and team; Rodrigo Pereira Martins** - which involves the production, maintenance and/or use of animals belonging to the phylum Chordata, subphylum Vertebrata (except human beings), for scientific research purposes or teaching - is in accordance with Law 11.794 of October 8, 2008, Decree 6899 of July 15, 2009, as well as with the rules issued by the National Council for Control of Animal Experimentation (CONCEA), and was **approved** by the Ethic Committee on Animal Use of the Federal University of Santa Maria (CEUA/UFSM) in the meeting of 03/23/2017.

Finalidade da Proposta: **Pesquisa (Acadêmica)**

Vigência da Proposta: de **04/2017** a **12/2018**

Área: **Morfologia**

Origem: **Biotério Central UFSM**

Espécie: **Ratos heterogênicos**

sexo: **Machos**

Idade: **2 a 3 meses**

N: **160**

Linhagem: **Wistar**

Peso: **200 a 300 g**

Resumo: A prática esportiva pode induzir lesões nas fibras musculares, gerando um dano oxidativo e processo inflamatório. Práticas terapêutica vem sendo utilizadas com o intuito de reduzir estes danos, como o plasma rico em plaquetas (PRP) e a crioterapia. Assim, o presente estudo tem como objetivo investigar através de experimentos bioquímicos a influência do tratamento com o frio terapêutico e/ou PRP em modelos de lesões musculares. Métodos: Serão aplicados protocolos de lesão muscular por contusão, distensão ou estiramento muscular. Imediatamente, os animais receberão uma dose, intramuscular de PRP e/ou serão submetidos a sessões de terapia com gelo. As análises bioquímicas serão realizadas 1, 3, 5, 7 e 14 dias após o primeiro dia de tratamento.

Local do experimento: Laboratório de bioquímica toxicológica experimental, prédio 19 sala 3122

Santa Maria, 10 de agosto de 2018

Prof. Dr. Denis Broock Rosemberg
Coordenador da Comissão de Ética no Uso de Animais
Universidade Federal de Santa Maria

Prof. Dr. Saulo Tadeu Lemos Pinto Filho
Vice-Coodenador da Comissão de Ética no Uso de Animais
Universidade Federal de Santa Maria

ANEXO C: NORMAS DA REVISTA *THE AMERICAN JOURNAL OF SPORTS MEDICINE*

1. Manuscript Submission Guidelines

Manuscripts must not be under simultaneous consideration by any other publication, before or during the peer-review process. Papers presented at AOSSM meetings must be submitted to the Journal for first rights of refusal. Articles published in *AJSM* may not be published elsewhere without written permission from the publisher.

Manuscripts should cite any other work by one or more of the co-authors that is relevant to the subject matter of the current submission or that used any of the same subjects, animals, or specimens being reported in the current submission. This includes manuscripts that are currently under preparation, are being considered by journals, are accepted for publication, or already published. In any of these cases, the relationship to the current submission should be made clear.

All review articles (such as systematic review, meta-analysis) submitted will be considered for the Current Concepts section. Authors with ideas for current concepts should contact the associate editor, Timothy Foster, MD, to find out if *AJSM* has recently published a review article on that topic or if there is a similar submission in progress. Contact Dr. Foster at info@ajsm.org to inquire about your idea or submit already completed papers directly to the journal at <https://submit.ajsm.org>.

2. Submissions

Authors should register on our online submission site at <https://submit.ajsm.org> to submit manuscripts.

When manuscripts have been received by the editorial office, the corresponding author will be sent an acknowledgment giving an assigned manuscript number, which should be used with all subsequent correspondence for anything related to that particular manuscript.

The following items are required on submission:

1. Blinded manuscript including the abstract and any tables and figures where they occur in the text. No identifying information should appear in the uploaded manuscript. Please remove author names, initials, and institutions. State or country names may be used, but do not include specific locations such as cities or regions.
2. Journal Contributor Publishing Agreement and *AJSM* Author Disclosure Statement. These forms are available for download from the author area of the submission site. The corresponding author must complete the forms and return them to *AJSM* by email or upload them online as a PDF or Word file using the “upload legal documents” option. As an alternative to the *AJSM* disclosure form, authors may submit the ICMJE disclosure form *along with* the *AJSM* Supplemental Form available on our website.
3. A copy of the IRB or other agency approval (or waiver) if animal subjects or human subjects or tissues or health information were used. Please see further

instructions under "Text." This information should be uploaded with the disclosure and publishing forms and not as a supplemental file.

4. The original study protocol for all registered clinical trials must be included and can be uploaded as a supplemental file. This information should be blinded for peer review (remove author name and location as well as trial registration number). Use of a CONSORT flow diagram is required to illustrate the grouping and flow of patients for all randomized clinical trials. The CONSORT checklist must also be completed and uploaded as a supplemental file.

Cover letter, acknowledgments, and suggested reviewers are optional. If a paper has more than 5 authors, a cover letter detailing the contributions of all authors should be included in the appropriate box on the submission page. Only those involved in writing the paper should be included in the author line. Others should be listed as a footnote or acknowledgment. While there is no limit on the number of authors, no more than 12 will be listed on the masthead of the published article; additional authors will be listed at the end of the article.

3. Manuscript Formats

Manuscript pages should be double-spaced with consecutive page numbers and continuous line numbers. The abstract should be included with the manuscript as well as being entered in the Metadata section (except for case reports, which do not require abstracts). Manuscripts should be 6000 words or fewer (including abstract and references). There are also limitations on figures, tables, and references; see guidelines below. The system handles most common word processing formats; however, Word and PDF are preferred.

4. Manuscript Preparation

4.1 Abstract

Abstracts should summarize the contents of the article in 350 words or less. The abstract should be structured in the following format:

Background: In one or two sentences, summarize the scientific body of knowledge surrounding your study and how this led to your investigation.

Hypothesis/Purpose: State the theory(ies) that you are attempting to prove or disprove by your study or the purpose if no hypothesis exists.

Study Design: Identify the overall design of your study. See list below.

Methods: Succinctly summarize the overall methods you used in your investigation. Include the study population, type of intervention, method of data collection, and length of the study.

Results: Report the most important results of your study. Only include positive results that are statistically significant, or important negative results that are supported by adequate power. Report actual data, not just *P* values.

Conclusion: State the answer to your original question or hypothesis. Summarize the most important conclusions that can be directly drawn from your study.

Clinical Relevance: If yours was a laboratory study, describe its relevance to clinical sports medicine.

Key Terms: Include at least 4 key terms for indexing. When submitting an article, you will be asked to choose from a list of terms that are used for assigning reviewers. These terms can be used in the manuscript as well. The list can be found at <https://submit.ajsm.org/submission/editexpertise>.

What is known about the subject: Please state what is currently known about this subject to place your study in perspective for the reviewers.

What this study adds to existing knowledge: Please state what this study adds to the existing knowledge.

The last two items are for reviewers only and are not included in the word count, but should appear at the end of the abstract in the uploaded text.

4.2 Study Designs

Meta-analysis: A systematic overview of studies that pools results of two or more studies to obtain an overall answer to a question or interest. Summarizes quantitatively the evidence regarding a treatment, procedure, or association.

Systematic Review: An article that examines published material on a clearly described subject in a systematic way. There must be a description of how the evidence on this topic was tracked down, from what sources and with what inclusion and exclusion criteria.

Randomized Controlled Clinical Trial: A group of patients is randomized into an experimental group and a control group. These groups are followed up for the variables / outcomes of interest. **NOTE: All clinical trials started after January 1, 2016 must be registered at ClinicalTrials.gov or a similar database to be considered for publication.**

Crossover Study Design: The administration of two or more experimental therapies one after the other in a specified or random order to the same group of patients.

Cohort Study: Involves identification of two groups (cohorts) of patients, one which did receive the exposure of interest, and one which did not, and following these cohorts forward for the outcome of interest.

Case-Control Study: A study that involves identifying patients who have the outcome of interest (cases) and patients without the same outcome (controls), and looking back to see if they had the exposure of interest.

Cross-Sectional Study: The observation of a defined population at a single point in time or time interval. Exposure and outcome are determined simultaneously.

Case Series: Describes characteristics of a group of patients with a particular disease or who have undergone a particular procedure. Design may be prospective or retrospective. No control group is used in the study, although the discussion may compare the results to other published outcomes.

Case Report: Similar to the case series, except that only one or a small group of cases is reported.

Descriptive Epidemiology Study: Observational study describing the injuries occurring in a particular sport.

Controlled Laboratory Study: An in vitro or in vivo investigation in which 1 group receiving an experimental treatment is compared to 1 or more groups receiving no treatment or an alternate treatment.

Descriptive Laboratory Study: An in vivo or in vitro study that describes characteristics such as anatomy, physiology, or kinesiology of a broad range of subjects or a specific group of interest. Authors should choose the design that best fits the study.

The Editor will make the final determination of the study design and level of evidence based on the Center for Evidence Based Medicine guidelines.

4.3 Text

In general, follow the standard IMRAD (Introduction, Materials and Methods, Results, Discussion) format for writing scientific articles. The author is responsible for all statements made in the work, including copyeditor changes, which the author will have an opportunity to verify. Authors with limited fluency in English should have the paper reviewed or edited by a native English speaker to ensure clear presentation of the work.

Papers including human or animal subjects must include a statement of approval by appropriate agencies in the text, and a copy of the approval letter must be uploaded with the submission. If approval was not required, authors must upload a waiver statement from the appropriate agency. For human cadaveric specimens, please provide source (eg, donation to university anatomy program) and state if permission was obtained for use. Additionally, all studies involving animals must conform to ARRIVE guidelines. If available, please include the source of animal joint or tissue specimens. For case reports, include a letter from the patient granting permission for his/her information to be included in the publication.

Reports on surgery, except in rare instances, require a minimum follow-up of 2 years.

Use generic names of drugs or devices. If a particular brand was used in a study, insert the brand name along with the name and location of the manufacturer in parentheses after the generic name when the drug or device is first mentioned in the text.

Use metric units in measurements (centimeter vs inch, kilogram vs pound).

Abbreviations should be used sparingly. When abbreviations are used, give the full term followed by the abbreviation in parentheses the first time it is mentioned in the text, such as femur-ACL-tibia complex (FATC).

Use of a CONSORT flow diagram is required to illustrate the grouping and flow of patients in all randomized controlled trials and is recommended for all other types of clinical studies.

Statistical methods should be described in detail. Actual *P* values should be used unless less than .001. Reporting of 95% confidence intervals is encouraged.

4.4 Acknowledgment

Type the acknowledgments in the box provided on the submission page; do not include it in the manuscript. This information will be added to the accepted manuscript at the time of publication. Give credit to technical assistants and professional colleagues who contributed to the quality of the paper but are not listed as authors. Please briefly describe the contributions made by persons being acknowledged. **Note: anyone who has contributed to the preparation of the submitted text must be included on the author disclosure form, under Statement of Authorship, and his or her disclosures included there.**

4.5 References

References should be double-spaced in alphabetical order and numbered according to alphabetical listing. Except for review articles, references should be limited to 60. If references are not in alphabetical order the uploaded file will be REJECTED and will have to be resubmitted with the references in the correct form. When author entries are the same, alphabetize by the first word of the title. In general, use the Index Medicus form for abbreviating journal titles and the *AMA Manual of Style* (10th ed) for format. *Note:* References must be retrievable. Do not include in the reference list meeting presentations that have not been published. Data such as presentations and articles that have been submitted for publication but have not been accepted must be put in the text as unpublished data immediately after mention of the information (for example, "Smith and Jones (unpublished data, 2000) noted ... "). Personal communications and other references to unpublished data are discouraged. For review purposes, unpublished references that are closely related to the submitted paper or are important for understanding it should be uploaded as supplemental files.

References will be linked to Medline citations for the reviewers. Authors can include articles that are in Epublish mode. To ensure that these Epub references are linked correctly, please provide the PMID number from Medline at the end of the reference. For example: Emery CA, Meeuwisse WH. Injury rates and mechanisms of injury in minor hockey. *Am J Sports Med.* 2006 Jul 21; [Epub ahead of print] PMID: 16861577

4.6 Figures and Tables

Figures and tables should appear in the body of the paper near the place where they are mentioned. High-resolution images should also be uploaded separately as Figure files. The figures and tables should be cited in numeric order in the text and should not exceed 3 journal pages. One journal page equals 1 large table or figure, 2 medium-sized tables or figures, or 4 small tables or figures. Medium-sized tables and figures will be a page width and half the length of the page; small tables and figures are 1-column width and take up half the length of the page or less.

Any material that is submitted with an article that has been reproduced from another source (that is, has been copyrighted previously) must conform to the current copyright regulations. It is the author's responsibility to obtain written permission for reproduction of copyrighted material and provide the editorial office with that documentation before the material will be reproduced in the Journal.

All image files for figures should be labeled with the Figure number (label each part if figures include multiple parts, eg, 2A, 2B). The figure legend should be placed below each figure and should include descriptions of each figure part and identify the meaning of any symbols or arrows. Terms used for labels and in the legend must be consistent with those in the text. A CONSORT flow diagram should be included for all randomized clinical trials to illustrate the grouping and flow of patients.

Color will be used in the Journal where needed (eg, histology slides or surgical photographs). All other figures, such as bar graphs and charts, should be submitted in black and white.

Figures for papers accepted for publication must meet the image resolution requirements of the publisher, SAGE Publications. Files for line-based drawings (no grayscale) should ideally be submitted in the format they were originally created; if submitting scanned versions, files should be 1200 dots per inch (dpi). Color photos should be submitted at 600 dpi and black-and-white photos at 300 dpi.

Charts and graphs can be submitted in the original form created (eg, Word, Excel, or PowerPoint). Photographs or scanned drawings embedded in Word or PowerPoint are not acceptable for publication.

All photographs of patients that disclose their identity must be accompanied by a signed photographic release granting permission for their likeness to be reproduced in the article. If this is not provided, the patient's eyes must be occluded to prevent recognition.

For tables, the system accepts most common word processing formats. Tables should have a title that describes the content and purpose of the table. Tables should enhance, not duplicate, information in the text.

4.7 Videos

Use of supplementary video is encouraged. Videos may be submitted with a manuscript and, if approved by the editor, will be posted online with the article when published. Video submission is strongly encouraged for manuscripts reporting surgical, examination, or exercise techniques or injury mechanisms. For more information about the format requirements for videos, please review the Video Format Guide. For detailed information pertaining to copyright and permissions requirements, view the Video Permission and Fair Use Quick Guide. For videos with identifiable subjects, subjects will need to sign the Audio-Visual Likeness Release form. It is the author's responsibility to submit signed release forms, if necessary, for each video.

5. Accepted Manuscripts

Once an article is accepted and typeset, authors will be required to carefully read and correct their manuscript proofs that have been copyedited by the publisher. Any extensive changes made by authors on the proofs will be charged to authors at the rate of \$2 a line. Authors are responsible for ordering reprints of their articles. Completed articles will be published on our website before print publication.

6. NIH-Supported Studies

Authors of studies funded by grants from the National Institutes of Health can deposit a copy of their accepted final peer-reviewed manuscript and associated figure/table files (pre-typeset versions) to the NIH database after a 12-month embargo period from the time their article is published in *AJSM*.

7. Important Notice on Plagiarism and Copyright Infringement

AJSM and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of articles published in the journal. Equally, we seek to protect the reputation of the journal. Submitted articles may be checked using duplication-checking software. Where an article is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where authorship of the article is contested, or where data or other information found to be incorrect